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A total of 507 plant extracts from 174 South African plant species, selected based on their 
traditional uses against parasitic diseases, mainly against malaria were screened against 
Plasmodium falciprum, Trypanosoma brucei rhodesiense, Leishmania donovani and 
Trypanosoma cruzi.  One-hundred and seven (107) plant extracts showed more than 95% 
growth inhibition against one or more parasites and were considered active.  The IC50 values 
for these plant extracts in the different assays were determined as well as cytotoxicity 
evaluations.  Plant extracts of Hypericum aethiopicum leaves, Leonotis leonurus leaves, 
Ekebergia capensis fruits, Alepidea amatymbica whole plant, Asystasia gangetica leaves, 
Setaria megaphylla whole plant, Leonotis ocymifolia var ocymifolia leaves, Schefflera 
umbellifera, Salvia repens whole plant, and Tachonanthus camphorates exhibited IC50 values 
of ≤ 5 µg/ml, which was used as second criteria for selecting the plant extracts for 
phytochemical investigation.  The extracts of Schkuhria pinnata, Vernonia mespilifolia and 
Salvia repens showed promising activity against the parasites of T. b. rhodesiense, P. 
falciparum and L. donovani.  In a medium throughput screening, 64 extracts inhibited the 
growth of one or more parasites to more than 95% at a concentration of 9.7 µg/ml  The most 
notable results are the antitrypanosomal activities of S. pinnata (IC50 value of 2.04 µg/ml) 
and V. mespilifolia (1.01 µg/ml).  S. repens whole plant extract showed anitleishmanial 
activity with an IC50 value of 5.4 µg/ml and cytotoxicity tests against myoblast L6 cells 
resulted in an IC50 of 41.5 µg/ml. 
 
With the aid of a HPLC-based activity profiling technique four compounds (P3-1, P4-1, P4-2 
and P4-3) from these three plant species were identified and characterised as the active 
compounds responsible for the observed activities against the parasites, T. b. rhodesiesnse, P. 
falciparum and L. donovani.  Sesquiterpene lactones, schkuhrin I (P4-1) and schkuhrin II 
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(P4-2) from S. pinnata and cynaropicrin (P4-3) from V. mespilifolia were isolated while 12-
methoxycarnosic acid (P3-1) was isolated from S. repens.  Cynaropicrin (P4-3) was the most 
active sesquiterpene lactone against T. b. rhodesiense (0.23 µM).  However, its antiprotozoal 
activity might be attributed to its toxicity as indicated by cytotoxicity against rat myoblast 
cells (IC50 of 1.29 µM).  The sesquiterpene lactones (P4-1 and P4-2) from S. pinnata showed 
promising activity against T. b. rhodesiense (IC50 values of 0.86 and 1.50 µM).  However, 
compounds P4-1 and P4-2 exhibited toxic effects against rat myoblast cells with IC50 values 
of 5.26 and 9.03 µM.  Therefore, they are not excellent candidates as lead compounds against 
T. b. rhodesiense.  While compounds P4-1-P4-3 and P3-1 were shown to be toxic, 
derivatisation of the compounds, which would change the structure and render them non-
toxic could be useful if the derivatised compounds show similar activity against these 
parasites. 
 
12-Methoxycarnosic acid (P3-1) showed antileishmanial activity (IC50 of 0.75 µM) and 
cytotoxicity against L6-cells (IC50, 17.3 µM).  The selectivitiy index of 23 indicates that P3-1 
is moderately toxic against the rat myoblast cells.  However, it is not a good potential to be 
considered as a lead drug against leishmaniasis but possible derivatisation of the compound 



































Structures of the isolated compounds schkuhrin I (P4-1) and schkuhrin II (P4-2) from 
Schkuhria. Pinnata, cynaropicrin (P4-3) from Vernonia mespilifolia and 12-methoxycarnosic 
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Infectious and parasitic diseases pose a global problem to the human population.  The 
neglected tropical diseases (NTDs) are a subset of infectious diseases caused by 13 parasitic 
and bacterial infections[1, 2] and include three vector-borne protozoan infections (human 
African trypanosomiasis, Leishmaniasis and Chagas disease), three bacterial infections 
(trachoma, leprosy and Buruli ulcer) and seven helminth infections (hookworm, ascariasis, 
trichuriasis, lymphatic filariasis, onchocerciasis, drancunculiasis and schistosomiasis) [3].  
The parasitic and bacterial infections responsible for these diseases are listed in table 1.1 [3].   
NTDs mostly occur in rural and impoverished urban areas of low-income countries.  They 
have the deleterious effect of impairing childhood growth, intellectual development, 
education and worker productivity [4].  The cause of these diseases are partly attributed to 
inadequate access to clean water, poor sanitation, and shack dwelling and apart from 
disfiguring patients there is also a stigma attached to the diseases [2, 4]. 
 
NTDs cause an estimated 534 000 deaths annually [4], which place a large burden on 
healthcare demands and economic development of low-income countries.  In addition, 
approximately 57 million disability-adjusted life years (DALYs) are lost due to premature 
disability and death per year [5], an even greater burden than those for malaria and 
tuberculosis [6].  NTDs represent the fourth most important group of communicable diseases 
worldwide behind lower respiratory infections, Human Immunodeficiency virus/Acquired 
immunodeficiency syndrome (HIV/AIDS) and diarrheal diseases [4] and are the second only 
to HIV/AIDS as a cause of disease burden [3]. 
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Table 3.1 The 13 parasitic and bacterial infections responsible for neglected tropical diseases 
(NTDs) around the world [3] 
Etiological agent Parasitic diseases 
Protozoan 
Leishmania donovani Visceral leishmaniasis (Kala-azar) 
Trypanosoma gambiense and Trypanosoma 
brucei rhodesiense 
African trypanosomiasis (African 
sleeping sickness) 
Trypanosoma cruzi American trypanosomiasis (Chagas 
disease) 
Helminth 
Schistosoma mansoni, S. haematobium, S. 
japonicum 
Schistosomiasis 
Wuchereria bancrofti and Brugia malayi Lymphatic filariasis (elephantiasis) 
Onchocerca volvulus Onchocerciasis (river blindness) 
Dracunculiasis medinensis Drancunculiasis (guinea worm) 
Ascaris lumbricoides Ascariasis (roundworm) 
Trichuris trichiura Trichuriasis (whipworm) 
Necator americanus and Ancylostoma duodenale Hookworm 
Bacterial 
Mycobacterium leprae Leprosy 
Mycobacterium ulcerans Buruli ulcer 
Chlamydia trachomitis Trachoma 
 
In September 2000, world leaders at the United Nations adopted the Millennium Declaration, 
which established eight millennium development goals to eliminate extreme poverty, hunger 
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and disease by 2015.  The sixth goal specifically focuses on health and economic impact of 
infectious diseases by combating malaria, tuberculosis and HIV/AIDS.  This goal has led to 
considerable and welcomed large scale financial injection through initiatives sponsored by 
the group of eight (G8) governments to fight HIV/AIDS and malaria [1].  However, until 
recently, programs to combat other diseases like NTDs have not benefited from these support 
systems.  For the scope of this project, only three vector-borne protozoan infections 
(Trypanosoma brucei rhodesiense, Leishmania donovani and Trypanosoma cruzi) and 
malaria (Plasmodium falciparum) are investigated. 
 
1.1 Malaria 
Malaria is one of the most dangerous parasitic infections with severe public health and 
development challenges worldwide, mainly in the tropical and subtropical areas [7].  It is a 
mosquito-borne disease caused by four protozoan parasites of the genus Plasmodium (P. 
vivax, P. ovale, P. malariaeand P. falciparum) that infect the red blood cells.  P. falciparum 
is responsible for a large proportion of morbidity and most malaria deaths in endemic regions 
[8].  It is transmitted to people through the bites of infected Anopheles mosquitoes, called 
“malaria vectors”and is characterized by symptoms of fever, headache, chills and vomiting 
which appear seven days or more after infection [9].  If left untreated within 24 hours, P. 
falciparum malaria can progress to severe illness often leading to death.  In children, severe 
anaemia, respiratory distress in relation to metabolic acidosis and cerebral malaria may 
frequently develop [10]. 
 
In 2010, an estimated 216 million cases of malaria were reported per annum with an 
estimated 655 000 deaths with 86% of these deaths being children [9, 11].  This indicated a 
marginal reduction in the number of deaths (863 000) reported in 2008 [12].  In sub-Saharan 
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Africa, P. falciparum accounts for approximately 90% of the cases and almost all malaria 
deaths each year, mainly in African children under the age of 5 years and in pregnant woman 
[9].  Economically, malaria slows the economic growth by 13% per year which translates into 
a gross domestic product cost in sub-Saharan Africa of US$ 12 billion per year, causing 
severe economic consequences to the poor areas of the sub-Saharan region [13], preventing 
improvement and advancement in both the economy and living standards and places serious 
constraints on the country’s ability to fund and maintain programmes that could control 
malaria [8]. 
 
1.1.1 Malaria and HIV/AIDS co-infections 
In 2011, an estimated 2.5 million people were newly infected with HIV resulting in over 34.2 
million people living with HIV globally, and over 1.7 million deaths annually.  An estimated 
23.5 million of the total HIV infected population were residing in the sub-Saharan African 
region alone with 1.7 million infections being new cases.  The annual mortality rate arising 
from the disease in sub-Saharan Africa is over 1.2 million people [14].  Malaria, reported as 
one of the leading causes of HIV-related morbidity in sub-Saharan Africa [16] is responsible 
for an estimated 91% deaths in sub-Saharan Africa [9, 11].  There is considerable 
geographical overlap between the two diseases with the most severely affected areas being 
Zambia, Zimbabwe, Mozambique, Malawi and the Central African Republic [15]. 
 
HIV has been shown to increase the risk of malaria infection and the development of clinical 
malaria, with the greatest impact in immune-suppressed individuals [17-19].  Conversely, 
malaria has been shown to increase the viral load by inducing HIV-1 replication both in vitro 
and in vivo [20, 21].  In 2004, Grimwade and co- investigators conducted a study in Hlabisa 
district, KwaZulu-Natal, South Africa in a total of 1109 malaria antigen-positive patients 
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[18].  In this study 613 patients were confirmed microscopically to have been suffering from 
malaria.  In addition, 180 (29.4%) of the 613 microscopically confirmed patients were HIV 
positive and 152 (30.6%) of the 496 unconfirmed patients were also HIV positive resulting in 
the total number of 332 (29.9%) HIV patients co-infected with malaria.  The results 
suggested that HIV infection increases the risk of severe malaria and subsequently also 
increases the risk of death [18]. 
 
In a similar study conducted by Cohen and colleagues at Chris Hani Baragwanath hospital, 
Johannesburg, South Africa, 336 patients were enrolled in the study to assess the impact of 
HIV infection on the risk of severe malaria [22].  In this study, 110 (33%) patients were HIV 
positive and 111 (33%) patients were non-immune (born or residing in an area without stable 
malaria transmission) and 225 (68%) patients were semi-immune (born and spent at least 5 
years of childhood in an area with high levels of malaria transmission).  HIV-infected 
patients in the non-immune group showed greater incidences of severe malaria than the semi-
immune group [22].  This suggested that HIV infection is associated with an increased risk of 
severe malaria, probably because of an impaired immune response to the malaria parasite 
leading to a decreased ability to control parasitemia.  In addition, severe malaria was more 
common in patients with a CD4+ T cell count <200 × 106 cells/L [22]. 
 
1.1.2 Current antimalarial drugs and resistance development 
Malaria is one of the most infectious diseases in the world and the emergence of resistance to 
available drugs is a major contributing factor to most of malaria-associated deaths in endemic 
regions [23, 24].  The discovery of quinine (1), the first antimalarial drug in the 17th century 
from the bark of Cinchona calisaya and the subsequent discovery of artemisinin (2) – also 
known as Qinghaosu - in the 1970s from a Chinese medicinal plant, Artemisia annua 
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commonly known as “qinghao”, contributed significantly to the treatment and eradication of 
malaria for many years [25].  Currently, several classes of antimalarials (quinoline 
derivatives, antifolates, artemisinin derivatives and antimicrobials) have been developed and 






Besides being used to combat malaria, currently used antimalarials also have certain 
liabilities like toxicity, poor compliance, rapid resistance development and are extremely 
costly in developing countries.  The synthetic derivatives of quinine (1) such as 8-
aminoquinoline (primaquine) and 4-aminoquinoline (chloroquine) have played a significant 
role in the control and eradication of malaria in endemic regions.  In addition, the synthesis of 
chloroquine-like drugs led to the discovery of lumefantrine, piperaquine and pyronanidine in 
China and amodiaquine, mefloquine and halofantrine in the United States [29].  These 
quinine drugs cause parasite death by blocking the polymerization of the toxic by-products of 
haemoglobin degradation into insoluble and non-toxic pigment granules, resulting in cell 
lysis and parasite cell autodigestion [30]. 
 













1.2 Human African Trypanosomiasis 
Human African trypanosomiasis (HAT) also known as sleeping sickness is a disease caused 
by protozoan parasites of the genus Trypanosoma, single-celled organisms that remain in 
extracellular form in the host.  There are two forms of the human disease, the East and 
Southern African variant caused by Trypanosoma brucei rhodesiense and the West African 
form caused by Trypanosoma brucei gambiense.  This disease is transmitted in both humans 
and cattle by the bite of a blood-sucking tsetse fly of the Glossina species.  Animals are the 
main host for the T. b. rhodesiense parasite while humans host the T. b. gambiense parasites.  
HAT is a major threat to the health of 60 million people living in 36 countries in the sub-
Saharan African (SSA) region and is the world’s third most important parasitic disease 
affecting human health after malaria and schistosomiasis, as defined by the global burden of 
parasitic diseases, calculated as the disability adjusted life years (DALYs) lost.  This disease 
is very fatal if left untreated resulting in high mortality rates in endemic regions [31]. 
 
In the 1960s, HAT caused by T. b. gambiense was controlled in Central Africa as a result of 
effective surveillance programs but it quickly re-emerged with a progressive increase in the 
numbers of new cases and deaths [32].  In the last decade, the number of new cases reported 
per annum in major endemic countries in SSA has decreased considerably as a result of 
increased public health.  In 2005, an estimated 50 000-70 000 cases of HAT were reported in 
SSA with only 17 616 cases reported as new but this number has been significantly reduced 
in recent years [31, 32].  Recently, the World health organization (WHO) reported an 
estimated 30 000 cases of HAT in endemic regions and only 7139 new cases per annum.  
Most of the new cases of HAT were reported in the Democratic Republic of Congo (DRC) 
with over 500 new cases.  Some of the countries included Angola, Central African Republic, 




In the host, the parasite (T. b. rhodesiense or T. b. gambiense) invades the lymph nodes and 
systemic organs such as the liver, spleen, heart, eyes and endocrine systems immediately after 
one to three weeks of infection.  This stage is termed the hemolymphatic stage (stage 1) and 
if left untreated for a few weeks (T. b. rhodesiense) or many months (T. b. gambiense), the 
parasites cross the blood-brain barrier (BBB) and enters the central nervous system (CNS).  
This stage is termed the encephalitic stage (stage 2) of the disease [31].  In the 
hemolymphatic stage, HAT is characterised by nonspecific symptoms such as weight loss, 
headache, malaise, arthralgia, fatigue, fever and vomiting [31].  The encephalitic stage is 
characterised by sleeping disturbances, psychiatric and mental features, motor and sensory 
disturbances and visual involvement [33]. 
 
1.2.1 Human African Trypanosomiasis and HIV/AIDS co-infections 
Human African Trypanosomiasis (HAT) and HIV/AIDS are endemic in most of the sub-
Saharan countries making co-infections very common, which poses a major socio-economic 
and public health problem in these countries.  The impacts of HIV/AIDS on the epidemiology 
and/or clinical manifestation of HAT are still very unclear.  However, few studies have 
shown that HIV-infected patients might be at a higher risk of treatment failure and 
unfavourable outcomes [34, 35].  Recent reports have shown a few cases of HIV and HAT 
co-infection [36, 37]. 
 
1.2.2 Current antitrypanosomal drugs and resistance development 
Currently, four drugs discovered decades ago are used in the treatment of HAT [38].  In 
addition, these drugs have unacceptable toxicity, an undesirable route of administration, is 
very expensive and not effective at all stages of the disease [38, 39].  Three of the drugs, 
9 
 
suramin (3), pentamidine (4) and melasoprol (5) were developed during the first half of the 
twentieth century and the last drug to be registered for HAT, DL-α-difluoromethylornithine 
(DFMO) (6) was registered in 1990 [31, 33, 38].  In the hemolymphatic stage, suramin (3) 
and pentamidine (4), discovered in 1921 and 1941, respectively are used as the drugs of 
choice against T. b. rhodesiense and T. b. gambiense, respectively because they are not able 
to cross the BBB [31, 33, 39].  Suramin (3) can also be used as an alternative therapy against 
T. b. gambiense [33]. 
 
In the encephalitic stage, melasoprol (5), discovered in 1949 is used against both T. b. 
rhodesiense and T. b. gambiense.  However, DL-α-difluoromethylornithine (6) is used against 
T. b. gambiense only [31, 33].  Recent developments have led to the use of nifurtomix (8) - 
DL-α-difluoromethylornithine (6) combination as an alternative treatment for T. b. gambiense 
in the encephalitic stage [31, 33] and is provided free of charge by the WHO [31].  The 
following paragraphs will provide an in depth knowledge about the possible mode of 






Figure 1.5 Structures of some of the currently used antiprotozoal drugs [Suramin (3), 
Pentamidine (4), Melasoprol (5), DL-α-difluoromethylornithine (6), Benznidazole (7), 
Nifurtimox (8) and Miltefosine (9)] against T. b. rhodesiense, L. donovani and T. cruzi 
 
Suramin (3) is a colourless, polyanionic sulfonated napthylamine that is highly soluble in 
water and has to be given intravenously by injection [38].  Some of the immediate adverse 
effects include collapse with nausea, vomiting and shock.  Severe delayed reactions include 






























































anaemia, jaundice and severe diarrhoea, all of which can be fatal [38].  Unfortunately, 
suramin (3) does not penetrate well into the CNS and is therefore only effective in the 
hemolymphatic stage [38].  The mode of action of suramin in killing trypanosomes is still not 
known and its action is very slow [38].  It has been suggested that the action of suramin (3) 
involves inhibition of various glycolytic enzymes such as reverse transcriptase, dihydrofolate 
reductase, fumarase, glycerol-3-phosphate dehydrogenase, hexokinase, L-α-glycerophosphate 
oxidase, receptor mediated uptake of low-density lipoprotein (LDL), RNA polymerase and 
kinases, thymidine kinases and trypsin [40, 41, 42].  Vansterkenburg and co-authors 
suggested that deprivation of the parasite from cholesterol and phospholipids by an inhibition 
of the uptake of LDL contributes to the mode of action of suramin (3) against trypanosomes 
[43].  No significant clinical resistance against suramin (3) has emerged despite its use for 
many decades [38]. 
 
Pentamidine (4), an aromatic diamidine remains the drug of choice for early T. b. gambiense 
infections [44].  Unfortunately, pentamidine (4) has poor oral bioavailability because it is 
highly protonated at physiological pH, hence it is given intramuscularly for a week [38, 44].  
Generally, pentamidine (4) is well tolerated but when given by intramuscular injection, site 
pain and transient swelling, abdominal pain, gastrointestinal problems, hypoglycaemia, 
hypocalcemia and renal failure are frequently reported [41, 44].  The mode of action of 
pentamidine (4) has not been established [38, 45].  However, its toxic effect could arise from 
the inhibition of multiple cellular targets [45].  Vercesi and Docampo suggested that, 
pentamidine (4) decreases the mitochondrial membrane potential of trypanosomatids [46] and 
act as an uncoupler of oxidative phosphorylation in mammalian mitochondria [47].  It also 
selectively inhibits the plasma membrane Ca2+ ATPase in T. b. brucei [48].  Resistance to 




Melasoprol (5), an organoarsenic compound, remains the most widely used drug for the 
treatment of encephalitic stage HAT caused by both T. b. gambiense and T. b. rhodesiense in 
resource-poor countries where DL-α-difluoromethylornithine (6) is not available or 
affordable [38, 44].  Melasoprol (5) is practically insoluble in water and must be given 
intravenously dissolved in propylene glycol [38].  Adverse reactions are frequent and can be 
severe or even life-threatening.  The most important reaction is an encephalopathic syndrome 
which occurs in 5-10% of the cases [41, 44].  Other common side effects include vomiting, 
abdominal colic, peripheral neuropathy, arthralgia and thrombophlebitis [38].  Due to these 
adverse effects particularly, encephalopathy, safer alternatives to melasoprol (5) are needed 
urgently.  Treatment failures have occurred in 30% of those treated, suggesting the 
emergence of resistance to melasoprol [44]. 
 
DL-α-difluoromethylornithine (6) is the only drug that has been recently registered for the 
treatment of human African trypanosomiasis [31, 33, 38, 44] recently.  It is an analogue of 
the anticancer agent ornithine [45].  DL-α-difluoromethylornithine (6) is recommended as the 
first-line treatment for second stage T. b. gambiense infections [31, 33, 38] and is 
administered by continuous infusion because of the short half-life of the drug [44].  It has a 
slow action and is trypanostatic rather than trypanocidal [41].  It is also poorly absorbed and 
rapidly excreted in the urine [42].  Adverse drug reactions include bone marrow toxicity 
leading to anaemia, leucopenia and thrombocytopenia, gastrointestinal symptoms and 
convulsions [49].  Its mode of action is through the suicide inhibition of ornithine 
decarboxylase, the key enzyme in the pathway leading to the biosynthesis of polyamines: 
putrescine, spermidine and spermine which are essential for cell proliferation [45].  No drug 
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resistance has been reported in the field even though some drug-resistant mutants have been 
isolated in the laboratory [45]. 
 
The drugs mentioned above have significantly contributed to the eradication and treatment of 
human African trypanosomiasis in poor countries. However their associated toxicities, mode 
of administration and all the other challenges necessitates an urgent need in the discovery and 
development of novel drugs which are active at all stages of the disease, which is cheap, non-
toxic and can be easily administered in a short course. 
 
1.3 Leishmaniasis 
Leishmaniasis comprises a group of tropical diseases caused by twenty species of protozoan 
parasites belonging to the genus Leishmania.  These parasites cause one of four clinical forms 
of the diseases, cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), diffuse 
cutaneous leishmaniasis and visceral leishmaniasis (VL) [50].  The disease affects 
approximately 12 million people worldwide with around 2 million new cases reported 
annually in 88 countries.  A population of over 350 million individuals are at risk of infection 
in the tropic and subtropic regions of the world [51, 52].  Leishmaniasis is transmitted 
zoonotically by the female flying insects of the genus Phlebotomus sandflies in Africa, Asia 
and Europe and Lutzomyia in the Americas and Australasia [53]. 
 
Visceral leishmaniasis (VL) caused by Leishmania donovani is the most severe form of 
leishmaniasis.  It is associated with high mortality and morbidity rates in developing 
countries and remote areas around the world and can be very fatal if left untreated [54].  This 
agent affects around half a million people annually mainly in India, Nepal, Bangladesh, 
Sudan, Ethiopia, and Latin American countries such as Brazil [50, 53, 54].  In sub-Saharan 
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Africa, most visceral leishmaniasis cases are reported in the Horn of Africa, i.e., the east 
African countries of Sudan, Eritrea, Ethiopia, Kenya and Somalia [55].  The highest 
incidence of the disease occurs in Sudan where 15000-20000 new cases are reported 
annually, followed by Ethiopia with approximately 4000 new cases reported per annum [55, 
56].  Many cases occur in areas of conflict which has destroyed housing and health care 
infrastructure.  Forced human migrations make the disease burden estimates difficult.  
Increased malnutrition as a result of drought and human conflict contributed severely to the 
emergence and progression of visceral leishmaniasis in endemic countries [57]. 
 
Visceral leishmaniasis is characterised by fever, weight loss, hypergammaglobulinemia, 
pancytopenia and affects the internal organs, mainly the liver and spleen [58, 59].  These 
conditions are very fatal if treatment is not established in time. 
 
1.3.1 Leishmaniasisand HIV/AIDS co-infections 
Opportunistic infections (OIs) are one of the leading causes that result in a decline in the 
condition of HIV-infected patients. Of these, parasites play an important role as OIs and are 
one of the most common causes of morbidity and mortality in HIV/AIDS patients [61].  
Leishmaniasis is one of the two main systematic OIs reported in HIV-infected patients [61].  
It attacks the patient’s immune system, already compromised by HIV/AIDS, making the 
situation worse and the patient more susceptible to other infections such as tuberculosis and 
pneumonia.  The impact of the HIV/AIDS pandemic has modified the natural history of 
leishmaniasis.  HIV immunosuppression increases the risk of acquiring leishmaniasis by 100-
1000 times in endemic regions and encourages the development of relapsing and eventually 
drug resistant leishmaniasis.  The possible overlap of these two diseases is therefore very 
dangerous [63].  Recent increases in the prevalence of VL-HIV co-infections in Southern 
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Europe, South Asia, Brazil and sub-Saharan Africa has created interesting diagnostics and 
therapeutic problems. 
 
1.3.2 Current antileishmanial drugs 
Current treatment of leishmaniasis is primarily based on chemotherapy and to some extent 
immunotherapy [64] since there is no vaccine against this disease [65].  For many years, 
pentavalent antimonials (Sbv) such as sodium stibogluconate and meglumine antimoniate, 
introduced more than 50 years ago have been used as drugs of choice for the treatment of 
leishmaniasis [54].  The mechanism of action of these drugs is still unknown, but it is 
reported that their antileishmanial action is probably due to the in vivo reduction of the Sbv 
form to a more toxic trivalent antimonial (SbIII) form.  Generally, it is known that Sbv acts by 
inhibiting glucolysis, fatty acid beta-oxidation, ADP phosphorylation [66, 67] and DNA 
topoisomerase in the parasite [68].  It also alters the thiol-redox potential of the parasite by 
actively promoting efflux of the thiols, glutathione and trypanothione, thus rendering the 
parasite more susceptible to oxidative stress [69]. 
 
One main advantage of the antimonials is their low cost but adverse effects including cardiac 
arrhythmias, elevated hepatic transaminase blood levels, pancreatitis and pneumonitis [70, 
71].  The emergence of resistance against the pentavalent antimonials in the state of Bihar, 
India constituted a major problem in the treatment of visceral leishmaniasis.  This resistance 
was primarily acquired and driven mainly by inadequate treatment and poor compliance with 
these drugs [72].  Therefore, their administration has been abandoned in this area and 
replaced by the conventional amphotericin B, amacrolidepolyene antifungal antibiotic agent 
that has been used as a second-line treatment for visceral leishmaniasis since the 1960s.  This 
drug exhibits an excellent antileishmanial activity with more than 90-95% success rate in 
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India [73].  The introduction of amphotericin B lipid formulations has improved the safety 
profile of this drug.  Lipid formulations of amphotericin B: liposomal amphotericin B, 
amphotericin B lipid complex and amphotericin B cholesterol dispersion are taken selectively 
by the reticulo-endothelial system and exhibit a highly localized enhanced antileishmanial 
activity [74].  Frequent adverse effects related to amphotericin B treatment; include infusion-
related fever and chills, nephrotoxicity and hypokalemia [75]. 
 
Another current antileishmanial drug, paromomycin is an aminoglycosidic aminocyclitol 
isolated in 1956 from the Streptomyces riomosus var. paromomycinus.  Its antileishmanial 
activity has been reported in the 1960s by Neal [76].  Paromomycin has shown a 94.6% cure 
rate of visceral leishmaniasis in India in the phase III clinical trials [77].  Paromomycin 
inhibits protein synthesis and modifies membrane fluidity and permeability [74].  
Paromomycin related adverse effects include elevated hepatic transaminases, ototoxicity and 
pain at the site of injection [77]. 
 
An exciting new development in the treatment of visceral leishmaniasis has been the 
discovery of miltefosine (9), an alkylphospholipid, in the 1980s as a novel drug for the 
treatment of visceral leishmaniasis that can be administered orally in endemic countries [54].  
Based on its safety and efficacy profile, miltefosine (9) was registered in India in 2002 and 
subsequently in Germany in 2004 [78].  In a phase IV multicenter clinical trial, miltefosine 
(9) exhibited a cure rate of 82% per intention-to-treat analysis and 95% per protocol analysis 
in 1132 Indian visceral leishmaniasis patients [79].  In this study, adverse effects associated 
with miltefosine (9) treatment such as reversible gastrointestinal and renal toxicity, elevated 
hepatic transaminases and creatinine [79] were reported.  The major drawbacks of miltefosine 
(9) are the potential of teratogenicity and its long half-life (approximately 150 hours) which 
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may promote the emergence of resistance, endangering the life span of miltefosine (9) [59, 
74].  Miltefosine (9) is also forbidden in women of child-bearing age who may become 
pregnant up to two months of discontinuing the drug [80, 74]. 
 
Generally, many of the current antileishmanial drugs have disadvantages including the 
intramuscular route of administration and prolonged hospitalization and duration of treatment 
[70, 71].  Some drugs are very expensive as is the case with amphotericin B and its lipid 
formulations [73, 77] and their use is limited due to lack of efficacy [81, 82].  Emergence of 
resistance parasites and toxicity of these drugs is still a major concern in the treatment of 
visceral leishmaniasis [77]. 
 
1.4 Chagas disease 
Chagas disease, also known as American trypanosomiasis is caused by the protozoan 
parasite, Trypanosoma cruzi and was discovered in 1909 by the Brazilian physician Carlos 
Ribeiro Justiniano Chagas (1879-1934) [83, 84].  This disease is transmitted to humans and 
domestic and wild animals such as dogs, cats, guineapigs, rodents, armadillos and marsupials 
by large blood sucking insects of the subfamily Triatominae [85].  Three triatomine species, 
Triatoma infestans, Rhodnius prolixus and T. dimidiata are the most important vectors in the 
transmission of the parasite to humans [86, 87].  Commonly, infection is acquired through 
contact with the faeces of an infected triatomineor “kissing bug” while feeding on the host.  
The infected faecal droplets may be inadvertently be passed to the mucosa of the eye, nose or 
mouth causing infection to the host [88].  It can be transmitted through several mechanisms 
by blood transfusions, from mother to child (congenital transmission), through contaminated 
food like meat, sugar cane juice and fruit juice and accidental contamination during 




The disease is endemic in Latin American regions from northern Mexico to Argentina and 
some cases have been reported in the USA and Canada [83, 89, 90].  The WHO reported that 
an estimated 10 million people are infected with T. cruzi worldwide, mostly in Latin America 
with over 25 million people living at risk [83].  In the acute phase, Chagas disease infection is 
characterised by skin chancre (chagoma) or unilateral purplish orbital oedema (Romaña sign) 
with local lymphoadenopathies, and this can be accompanied by fever, headaches, abdominal 
pains, hepatomegaly, splenomegaly, myocarditis (chest pain and heart failure), and more 
rarely meningoencephalitis, especially in AIDS patients [83, 84].  Death occurs occasionally 
in the acute phase especially to children under the age of five [83, 84].  In the chronic phase, 
this disease hides in the heart and digestive smooth muscles and is characterised by 
arrhythmia, cardiomyopathy, heart failure, secondary thromboembolism, some digestive 
lesions such as megaoesophagus and megacolon and eventually death [83, 91-93]. 
 
1.4.1 Chagas disease and HIV/AIDS co-infections 
Due to the mass migration of rural inhabitants to big cities and an increase in poverty, this has 
led to co-infection of the disease with HIV and is a well-known opportunistic infection in 
people living with HIV/AIDS [94, 95]. 
 
Several non-endemic countries like Australia, Canada, Japan, Spain and the United States 
have observed an increased public health impact due to the overlap of HIV/AIDS infection 
and T. Cruzi [96].  In 2012, there were 74 deaths in which Chagas disease and HIV/AIDS 
were mentioned as the cause of death in which 57 (77%) was due to AIDS as the underlying 
cause and 13 (17.6%) being attributed to Chagas disease [96].  The most important clinical 
consequence to Chagas disease and HIV/AIDS co-infection is the reactivation of latent 
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(chronic) T. cruzi infection due to a suppressed immune system [94, 97].  Co-infection may 
also emerge as acute Chagas disease among those with AIDS living in Chagas endemic areas 
and acquiring recent T. cruzi infection [98].  This reactivation of Chagas disease may affect 
the central nervous system (CNS) with expansion lesions or meningoencephalitis and 
cardiopathy [99]. 
 
1.4.2 Treatment of Chagas disease and resistance development 
There is no vaccine for Chagas disease.  Currently, benznidazole (7) and nifurtimox (8) are 
used in the treatment of Chagas disease, which are completely effective when administered 
just after infection [83].  However, the efficacy of these drugs diminishes the longer a person 
has been infected [83].  Both drugs are not approved for use in the USA but can be obtained 
from the Center for Disease Control and Prevention (CDC) and used under investigational 
protocols [100]. 
 
Benznidazole (7) and nifurtimox (8) are nitroheterocyclic drugs that have been used for the 
treatment of Chagas disease for over forty years [101].  Generally, both drugs act through the 
formation of free radicals and/or electrophilic metabolites.  The nitro group of both drugs is 
reduced to an amino group by the action of nitroreductases, with the formation of various free 
radical intermediates and electrophilic metabolites.  These free radicals bind to lipids, 
proteins and DNA, damaging them [102].  The trypanocidal activity of benznidazole (7) does 
not entirely depend on free radical formation.  It has been shown that benznidazole (7) 
improves phagocytosis, increases trypanosomal death through IFN-γ [103], and inhibits T. 
cruzi NADH-fumarate reductase [104].  Some of the adverse effects associated with these 
drugs include systemic toxicity, anorexia, nausea, vomiting, headache, central nervous 
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system depression or maniacal symptoms, seizures, vertigo, paresthesias, peripheral 
polyneuropathy and dermatitis [105]. 
 
1.5 Natural products as antiparasitic agents 
The search for a new alternative treatment for protozoal diseases among plants has developed 
momentum in the drug discovery and development programs for several years [106, 107]. 
This search for better and less toxic novel substances derived from natural products has been 
based on the ethno-medicinal use of the plants by the indigenous population in endemic 
areas.  Several reviews have listed plants and natural product derivatives that showed some 
level of promising antiparasitic activity [108, 109].  Plant extracts and natural compounds 
from these medicinal plants have shown very promising antiprotozoal activities and most 
importantly provide leads toward the discovery of novel molecules for the treatment of these 
diseases.  The following paragraphs will provide a rationale and reflect some of the research 
done over the years in the discovery of active antiprotozoal compounds from nature with 
particular emphasis on malaria, leishmaniasis, sleeping sickness and Chagas disease. 
 
1.5.1 Natural products with antileishmanial activity 
A review by Chan-Bacab and Peña-Rodríguez mentioned approximately 97 natural 
compounds that have shown very promising antileishmanial activity [108]. The most 
promising classes were terpenes: diterpenoids [110] and sesquiterpenes [111], phenolics, 
naphthoquinones [112, 113] and alkaloids [114].  The structures of some of the natural agents 
that have shown promising antiprotozoal activity are shown in Figure 1.3.  Among these is 
berberine (10), a quaternary isoquinolinic alkaloid with leishmanicidal activity found in plant 
families such as Annonaceae, Berberidaceae and Menispermaceae.  Plants from these 
families have been used in various folk remedies for the treatment of cutaneous 
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leishmaniasis, malaria and amoebiasis [115].  This metabolite has been used clinically for the 
treatment of leishmaniasis for over 50 years and it has been demonstrated that it possesses 
significant activity both in vitro and in vivo against several species of Leishmania [116]. 
 
Plumbagin (11), a naphthoquinone isolated from species of the genus Plumbago has shown 
antileishmanicidal activity with IC50 values of 0.42 and 1.1 µg/ml against L. donovani and L. 
amazonensis, respectively [117].  Diospyrin (12), a bis-naphthoquinone isolated from the 
bark of Diospyros montana (Ebenaceae) is reported to be active against promastigotes of L. 
donovani with a MIC of 1.0 µg/ml [118].  The oxygenated chalcone, licochalcone A (13) 
isolated from the roots of the Chinese licorice plant (Glycyrrhiza spp.) inhibits the in vitro 
growth of promastigotes of L. major and L. Donovani [119, 120].  Triterpenes such as ursolic 
acid (14) and betulinaldehyde (15) from the bark of Jacaranda copaia and the stem of 
Doliocarpus dentatus respectively have shown activity against the amastigotes of L. 
amazonensis [121, 122].  Even though some of the reported natural products have been used 
for centuries in folk medicine, none have been evaluated in clinical studies.  This might be 
attributed to the lack of promising activity when tested in vivo and also to the toxic effects of 
some of the compounds in experimental assays. 
 
1.5.2 Natural Products with antitrypanosomal activity 
The discovery of active antiprotozoal molecules from medicinal plants has been well 
documented.  Recent reviews by Uchiyama [123] and Izumi [124] have reported the 
antitrypanosomal activity of a wide variety of medicinal plant extracts and their constituents 
against T. cruzi.  Sixty-one compounds belonging to flavonoids, phenylpropanoids, 
monoterpenes, sesquiterpenes and diterpenes and 134 compounds isolated from plants have 
been reported as showing potent trypanocidal activity [123]. 
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The sesquiterpene lactone, helenalin (16), isolated from Helenium autumnale exhibited an 
IC50 value of 0.695 µM against T. cruzi [125].  Although many compounds have shown 
antitrypanosomal activity, to date none have been registered for clinical use, probably due to 
poor results when tested in vivo, unacceptable toxicity results in experimental assays and 
lower potency compared to the currently used drugs, benznidazole and nifurtimox [126].   
 
 
Figure 1.6 Structures of some of the natural products [Berberine (10), Plumbagin (11), 
Diospyrin (12), Licochalcone A (13), Ursolic acid (14), Betulinaldehyde (15) and Helenalin 



















































Several reviews have reported many medicinal plants being used in the treatment of human 
African trypanosomiasis (HAT) commonly known as sleeping sickness, most of which are 
used on the African continent where sleeping sickness is endemic [127, 128, 129].  There 
have been reports of a wide variety of medicinal plants being tested for antipyranosomal 
activity in Uganda, Côte ďIvoire, Benin and Sudan [127-130], the most being recorded in 
Côte ďIvoire with 88 plants being tested against T. b. rhodesiense [128].  The most active 
plant extracts were the roots of Albizia gummifera (IC50of 70 ng/ml), Enantia polycarpa (IC50 
of 0.5 µg/ml), Trichilia emetica (IC50 of 0.04 µg/ml) and Xanthium brasilicum (IC50 of 0.1 
µg/ml) against T. b. rhodesiense [127-129].  A subsequent bioassay-guided isolation of 
Xanthium brasilicum resulted in the identification of xanthanolides as the active compounds 
[129]. 
 
1.5.3 Natural Products as antimalarials 
In South Africa, medicinal plants are commonly used in healthcare to treat a range of 
ailments, which include malaria and its associated symptoms [131].  There are several reports 
of medicinal plants being used traditionally to treat malaria in South Africa [132, 133], Kenya 
[134], Zimbabwe [135] Congo [136], Brazil [137], Nigeria [138, 139] and Cameroon [140].  
The many medicinal plants used in the healthcare system are indicative of the crucial role that 
medicinal plants play in many developing countries.  These plants are also sources of novel 
plant-derived compounds which could be leads for pharmaceuticals against several diseases. 
 
Two of the currently used antimalarial drugs, quinine and artemisinin have originated from 
plant sources.  In the last ten years, five reviews have appeared with over 200 compounds 
isolated from medicinal plants showing antiplasmodial activity [141-145].  These compounds 
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were also in diverse classes of compounds such as alkaloids, quassinoids, terpenes, 
sesquiterpenes, triterpenoids, chalcones, flavonoids, xanthones, quinones, coumarins, 
limonoids and peptides.  The indole alkaloids were found to exhibit IC50 values under the 
micromolar range and with good selectivity index [143]. 
 
1.6 HPLC based activity profiling in drug discovery 
Many of the active compounds in plants have been discovered by the use of an essential 
technique, bioassay-guided fractionation.  However, in recent years the use of this technique 
in drug discovery has resulted in a number of setbacks, especially being criticised for finding 
already known active metabolites.  In addition, this technique is time consuming, tedious and 
not suited for a medium throughput setting [146].  The introduction of hyphenated analytical 
techniques such as LC/DAD-UV, LC/MS, GC/MS and LC/NMR in which a chromatographic 
separation is coupled online with one or more information rich detectors have revolutionised 
the discovery of novel molecules from natural products [147].  One important advantage of 
these techniques is the identification of known molecules at an early stage of discovery.  
Hence, the isolation of unknown active compounds is prioritised. 
 
Fractionation of complex mixtures such as medicinal plant extracts by High Performance 
Liquid Chromatography (HPLC) in deep-well microtiter plates in combination with a 
biological activity assay is extensively employed to unambiguously identify bioactive 
compounds [148].  Recently, several bioactive compounds have been isolated and identified 
by using a HPLC-based activity profiling technique [149-152].  This technique has been used 
extensively in recent times in the discovery of antiprotozoal agents from natural plants 
extracts [153-156].  Generally, in this approach sub-milligram amounts of extract are 
separated by analytical scale HPLC and automatically fractionated into 96 well plates.  The 
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microfractions obtained are submitted to the bioassay, and the resulting activity profile can be 
overlaid with the HPLC trace to correlate peaks of activity with peaks in the HPLC 
chromatogram.  On-line spectroscopic data (UV–Vis and MS) collected during separation, 
combined with database searches provide structural information on the active principles [146, 
153, 157] making the identification of known active metabolites possible at an early stage of 
discovery rather than wasting time in the isolation process of known molecules. 
 
1.7 Aim of the project 
The aim of this project was to use South African plants that have been preselected on the 
basis of indigenous knowledge for the discovery of molecules with in vitro activity against 
Trypanosoma brucei rhodesiense, Leishmania donovani, Plasmodium falciparum and 
Trypanosoma cruzi that causes neglected diseases.  The discovery of such molecules will 
ultimately lead to the development of new and improved pharmacotherapy for these diseases, 
and to a reduction in the number of fatalities and disabilities associated with these diseases in 
poor and disease endemic countries (DEC). 
 
To achieve this, a library of South African plant species with potential antiprotozoal activity 
would be identified and from this we would choose the most appropriate plants to work on 
phytochemically.  For the isolation of active compounds from some of the selected plant 
species, a relatively new technique, High Performance Liquid Chromatography (HPLC)-
based activity profiling was used to identify and isolate active compounds from relatively 
small amounts of plant material.  Using this technique, a small quantity (350 µg) of plant 
extract was fractionated into 96 well microtiter plates and subjected to assay screening, at the 
same time obtaining the MS and UV data of the extract followed by extensive off-line 
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analysis to identify the active molecule.  This technique is very usefull in the early 
identification of known plant constituents without isolating them. 
 
1.8 The objectives of the project 
The objectives of the project were as follows 
1. Screening of a focused library of preselected plants extracts in a medium throughput 
screening to identify a specific library of plant extracts with antiprotozoal activity. 
2. Selection of potential “hits” to be subjected to the HPLC-based activity profiling 
technique. 
3. HPLC semi-preparative isolation of active compounds from potential “hits”. 
4. Structure elucidation and characterization of the isolated active compounds. 
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Three hundred extracts were prepared from plants traditionally used in South Africa to treat 
malaria and were screened in vitro for activity against Trypanosoma brucei rhodesiense, 
Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum.  For the 43 extracts 
which inhibited the growth of one or more parasites to more than 95% at 9.7 µg/mL, the IC50 
values against all four protozoal parasites and cytotoxic IC50 values against rat myoblast L6 
cells were determined.  Amongst the most notable results are the activities of Agathosma 
apiculata (IC50 of 0.3 µg/mL) against Plasmodium falciparum and Salvia repens and 
Maytenus undata against Leishmania donovani with IC50 values of 5.4 µg/mL and 5.6 µg/mL, 
respectively.  This screening is the starting point for a HPLC based activity profiling project 
in antiprotozoal lead discovery. 
 
Keywords 
South Africa, antiprotozoal, T. b rhodesiense; T. cruzi; L. donovani; P. falciparum 
 
Introduction 
Half a billion people get infected with malaria every year, and 1-2 million die of the disease 
[1].  Up to thirty million people annually contract one of the so called “neglected tropical 
diseases”, Chagas disease, human African trypanosomiasis or leishmaniasis, and the three 
diseases lead to 120 000 deaths annually [2].  These diseases are all caused by protozoal 
parasites, are transmitted by insect vectors, and affect the poorest populations.  Malaria drugs 
are reasonably affordable, available and safe, yet few in number and increasingly 
compromised by resistances [3].  Only a few drugs are on the market to treat trypanosomatid 
infections (Trypanosoma and Leishmania), and their pharmacological profiles are insufficient 
by modern standards [1].  For decades, large pharmaceutical companies have been reluctant 
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to invest in the development of new drugs for economic reasons.  This may be changing 
though because there have been increasing drug discovery and development efforts in recent 
years from private initiatives and non-profit organizations.  The Medicines for Malaria 
Venture (MMV), for instance, has initialized research networks [4], and philanthropist 
organizations like the Bill and Melinda Gates foundation and others have contributed 
substantial assets to such endeavors [5].  
 
The goal  of this study was to evaluate the antiprotozoal potential of plants used by traditional 
communities in South Africa to treat malaria.  Extracts were screened against the most 
important protozoal parasites, Plasmodium falciparum (malaria), Trypanosoma cruzi (Chagas 
disease), Trypanosoma brucei rhodesiense (sleeping sickness) and Leishmania donovani 
(leishmaniasis).  This screening study forms the base for an ongoing HPLC based activity 
profiling project in antiprotozoal lead discovery.  This library had been previously screened 
for antiplasmodial activity against chloroquine sensitive Plasmodium falciparum D10 strain 
[6]. 
 
Material and methods 
Plant species selection 
Plants were collected from the wild at various locations in South Africa by different 
ethnobotanists based on their ethnomedicinal uses against parasitic diseases, mainly malaria.  
A list of these uses can be found in an earlier publication [6]. Voucher specimens were 
identified and deposited at the South African National Biodiversity Institute (SANBI) (Table 





Preparation of plant extracts 
The plant parts (roots, leaves, twigs, fruits and stem bark) were dried in an oven at 30 – 60 
°C. Dried plant material was ground to a coarse powder using a hammer mill and stored at 
ambient temperature prior to extraction.  Of each sample, 100–500 g of powdered material 
was sequentially extracted, typically with 1 L of cold dichloromethane (DCM), 
DCM/Methanol (MeOH) (1/1), MeOH, and purified water in 2 L glass jars with screw on 
lids.  The extracts were filtered; the plant material dried overnight in a fume hood and then 
extracted with the next more polar solvent.  Organic extracts were concentrated using a Buchi 
rotavapor (Essen, Germany) at a temperature below 45 °C and then further dried in vacuo at 
ambient temperature for 24 h.  The aqueous extracts were concentrated by freeze-drying.  The 
yields of the extracts, in terms of starting plant material, were recorded.  All dried extracts 
were stored at −20 °C.  Analytical grade solvents for extraction were purchased from Romil 
Pure Chemistry (Cambridge, UK).  HPLC grade water was obtained from a TKA Ultra Pure 
water purification system (Niederelbert, Germany). 
 
Evaluation of in vitro antiprotozoal activity 
Screening of the extract library against Plasmodium falciparum (K1 strain), Trypanosoma 
brucei rhodesiense (STIB 900 strain), Trypanosoma cruzi trypomastigote forms (Tulahuen 
strain), and Leishmania donovani (strain MHOM/ET/67/L82) was performed in 96 well 
plates at concentrations of 9.7 and 1.8 µg/mL.  Tests were done in duplicate and repeated 
twice.  IC50 values against the parasites as well as cytotoxic effects against rat myoblast (L6-
cells) were determined by serial dilution and repeated twice.  
  
Trypanosoma brucei rhodesiense (STIB 900) were grown in axenic medium as described by 
Baltz et al. [7].  The samples were tested using the Alamar Blue assay protocol [8] to 
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determine the 50% inhibitory concentration (IC50).  A Spectramax Gemini XS micro plate 
fluorescence reader (Molecular Devices Cooperation, Sunnyvale, CA) with excitation 
wavelength 536 nm and an emission wavelength 588 nm was used to measure the plates. 
Melarsoprol (Arsobal®, Sanofi-Aventis, Switzerland) was used as a reference drug (IC50= 
0.03 ± 0.01 µM).  The IC50 values were calculated by using Softmax Pro software (Molecular 
Devices Cooperation, Sunnyvale, CA).  
 
Trypanosoma cruzi trypomastigote forms (Tulahuen strain C2C4 containing β-galactosidase 
(Lac Z) gene) were cultured as described by Buckner et al. [9] in rat myoblast cells (L6-
cells).  Benznidazole (Sigma-Aldrich, Switzerland) was used as a standard drug (IC50= 0.48 
µg/mL).  After incubation, the substrate chlorophenyl red β-D-galactopyranoside agent 
CPRG/Nonident was added to all wells and a color change was developed within 2 to 6 h.  
The plates were read photometrically at 540 nm (Molecular Devices).  Data were evaluated 
and IC50 values calculated using Softmax Pro software (Molecular Devices). 
 
Axenically grown L. donovani amastigotes (strain MHOM/ET/67/L82) were grown and tests 
were done as previously described using the resazurin assay [10].  The plates were developed 
for 2-4 hours and read on a Spectramax Gemini XS micro plate fluorometer (Molecular 
Devices Cooperation) using an excitation wavelength of 536 nm and emission wavelength of 
588 nm.  Fluorescence development was measured and expressed as percentage of the 
negative control.  Miltifosine (VWR, Paisley, Scotland) was used as a reference drug (IC50= 
0.241 µg/mL).  Data were transferred to the graphic programme Softmax Pro (Molecular 




Screening of the extract library and determination of activity against Plasmodium falciparum 
K1 strain was done using a modified version of the 3H-hypoxanthine incorporation assay by 
Trager and Jensen [11].  After incubation the plates were harvested using a Betaplate cell 
harvester (Wallac, Switzerland) onto glass-fiber filters and washed.  The dried filters were 
inserted into plastic foils with 10 ml scintillation fluid.  The radioactivity was counted with a 
Betaplate liquid scintillation counter (Wallac, Switzerland) as counts per minute per well at 
each drug concentration and compared to the untreated controls.  Chloroquine was used as a 
positive control (IC50= 0.05 ± 0.01 µM).  IC50 values were calculated by linear interpolation.  
All assays were run in duplicate and repeated twice. 
 
The cytotoxicity assay was performed by a similar protocol as the Alamar Blue assay 
whereby L6-cells were seeded in 100 µl RPMI 1640 supplemented in 96-well micro titer 
plates (4000 cells/well).  Podophyllotoxin (Sigma-Aldrich, Switzerland) was used as the 
reference drug.  After 68 h of incubation under humidified 5% CO2 atmosphere, 10 µl of the 
Alamar blue marker was added to all wells.  The plates were incubated for an additional 2 h.  
A Spectramax Gemini XS micro plate fluorescence reader (Molecular Devices Cooperation, 
Sunnyvale, CA) was used to measure the plates (Molecular Devices) using an excitation 
wavelength of 536 nm and an emission wavelength of 588 nm.  The IC50 values were 
calculated by Softmax Pro software (Molecular Devices Cooperation, Sunnyvale, CA). 
 
Results and Discusion 
One hundred and seven medicinal plants were selected because they had a reported tradition 
of being used as antiparasitic remedies.  Dried plant parts were extracted using solvents of 
different polarity (DCM, DCM/MeOH (1:1), MeOH and water) to give 300 extracts [6].  In a 
first step the extracts were screened for their potential anti-parasitic properties against T. b. 
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rhodesiense, T. cruzi, L. donovani and P. falciparum at the test concentrations 9.7 and 1.6 
µg/mL (Appendix 1, Table 2.1, Page 89 - 108). 
 
In a second stage, extracts which in the first step had shown more than 95 % inhibition of one 
or more parasites at a test concentration of 9.7 µg/ml were selected as potential “hits” and 
their IC50 values against all four parasites as well as their cytotoxicity against rat myoblast 
cells (Appendix 1, Table 2.2, Page 109 - 111) were determined.  This enabled the direct 
comparison of activities, parasite specific actions and toxicities of each of our “hits”, and 
served as a basis for the selection of the most promising extracts for HPLC based activity 
profiling and identification of the active principles [10].  
 
In general, P. falciparum was the most sensitive protozoal parasite towards the extract 
library.  The most potent extract in the entire screen was the DCM/MeOH (1:1) extract of 
Agathosma apiculata (Rutaceae) with an IC50 of 0.21 µg/mL against P. falciparum.  Seven 
more lipophilic (DCM/MeOH (1:1)) extracts showed antiplasmodial IC50 values of under 5 
µg/mL: that of Hypericum aethiopicum leaves (IC50=2.4 µg/mL), Leonotis leonurus leaves 
(2.9 µg/mL), Ekebergia capensis fruits (3.5 µg/mL), Alepidea amatymbica whole plant (3.7 
µg/mL), Asystasia gangetica leaves (4.2 µg/mL), Setaria megaphylla whole plant (4.4 
µg/mL) and Leonotis ocymifolia var ocymifolia leaves (4.5 µg/mL).  Also, the DCM extract 
of Leonotis ocymifolia var ocymifolia leaves was very active (2.7 µg/mL) (Appendix 1, Table 
2.2, Page 109 - 111).  
 
Against Trypanosoma brucei rhodesiense the DCM/MeOH (1:1) extracts of Tarchonardus 
camphorates whole plant (3.9 µg/mL), Hypericum aethiopicum leaves (4.7 µg/mL), Leonotis 
ocymifolia var ocymifolia leaves (9.1 µg/mL), Croton menyhartii whole plant (8.8 µg/mL) 
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and the DCM extracts of Pentzia globosa roots (5.8 µg/mL), Vernonia oligocephala leaves 
(4.7 µg/mL), Artemisia afra leaves (9.6 µg/mL), and Leonotis ocymifolia var ocymifolia 
leaves (9.7 µg/mL) showed IC50 values lower than 10 µg/mL.  Three further DCM, eighteen 
DCM/MeOH extracts, and one MeOH extract had IC50 values between 10 and 20 µg/mL 
against Trypanosoma brucei (Appendix 1, Table 2.2, Page 109 - 111).  Despite the fact that 
most of the 43 “selected hits” showed relatively good activity against T. brucei, none showed 
selectivity towards this parasite, as it had been the case for the Plasmodium falciparum 
screen.  
 
Trypanosoma cruzi was the least sensitive protozoal test organism.  Three extracts, the 
DCM/MeOH extract of Hypericum aethiopicum leaves (18.1 µg/mL), the DCM extract of 
Catha edulis roots (19.1 µg/mL) and the DCM/MeOH extract of Tarchonardus camphoratus 
whole plant (18.6 µg/mL) inhibited T. cruzi with IC50 values under 20 µg/mL.  Seven extracts 
showed IC50 values of less than six µg/mL against Leishmania donovani.  These were the 
DCM/MeOH extract of Hypericum aethiopicum leaves (4.7 µg/mL), Leonotis leonurus 
leaves (4.7 µg/mL), Ekebergia capensis fruits (4.8 µg/mL), Schefflera umbellifera (5.0 
µg/mL), Salvia repens (5.4 µg/mL), Tachonanthus camphorates (4.9 µg/mL), and the DCM 
extract of Maytenus undata (5.6 µg/mL).  
 
We screened an extract library generated from plants selected for their traditional antimalarial 
use against the most important human protozoal parasites.  The goal was to identify extracts 
with potent and, ideally, selective activity against any one of the parasites.  These hits are 





The initial screening of this focused extract library delivered forty three “potential hits”.  
These were defined as samples with almost complete (> 95%) inhibition at 9.7 µg/mL.  
Twelve of them showed activity against Plasmodium falciparum, twenty eight against 
Trypanosoma brucei rhodesiense.  Six of these extracts were active against both parasites.  
Against Leishmania donovani, eleven extracts fulfilled the criteria for “potential hits”. Five of 
these were also active against T. brucei.  One extract, the DCM extract of Catha edulis roots, 
inhibited both P. falciparum and Leishmania, and the DCM/MeOH extract of Hypericum 
aethiopicum leaves inhibited the growth of all three parasites. No extract showed > 95 % 
inhibition of Trypanosoma cruziat 9.7 µg/mL.  This parasite is generally less sensitive than 
Trypanosoma brucei because it is an intracellular test system. 
 
In a second phase, the IC50 values of the 43 “potential hits” were determined against all the 
parasites and against L6 cells (Appendix 1, Table 2.1, Page 89 - 108).  Agathosma apiculata 
(Rutaceae) was exceptional in the sense that it was by far the most active extract against 
Plasmodium falciparum and showed at the same time good selectivity.  An IC50 of 0.3 µg/mL 
against Plasmodium compared to 43 µg/mL in L6 cells corresponded to a selectivity value of 
143.  The extract was also 140 times more active against P. falciparum than against T. cruzi, 
53 times more active than against Leishmania donovani, and 37 times more active than 
against T. brucei.  Nine of the 43 selected active extracts showed IC50 values of <10 µg/mL 
against Trypanosoma brucei rhodesiense (Appendix 1, Table 2.1, Page 89 - 108).  Yet, 
despite the relatively high activity, none showed selectivity towards this parasite. 
 
Salvia repens and Maytenus undata were shown to be preferentially active against 
Leishmania donovani, whilst showing only moderate cytotoxic effects (Appendix 1, Table 
2.1, Page 89 - 108).  The most active extracts against T. cruzi showed nonspecific effects.  
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The DCM/MeOH extracts of Hypericum aethiopicum leaves (18.1 µg/mL) and Tarchonardus 
camphoratus (18.6 µg/mL), and the DCM extract of Catha edulis roots (19.1 µg/mL) at the 
same time strongly inhibited L6 cells, which are their T. cruzi‘s host cells (Appendix 1, Table 
2.1, Page 89 - 108).  The DCM/MeOH and/or DCM extracts of Hypericum aethiopicum, 
Leonotis leonurus, Ekebergia capensis, Catha edulis, Asystasia gangetica, Schefflera 
umbellifera and Tarchonardus camphoratus all showed relatively high cytotoxicity, with IC50 
values < 20 µg/mL, and activities against most protozoal test organisms.  Therefore, these 
extracts were not shortlisted for further follow-up.  
 
Conclusions 
In summary, screening of our focused library led to a shortlist of extracts with high activity 
against Plasmodium falciparum, Trypanosoma brucei rhodesiense and Leishmania donovani 
in a primary screen.  The percents of inhibition at the two initial test concentrations were 
roughly indicative of the half maximum inhibition concentration (IC50 values) to be expected 
in the second stage of the screening.  Given the cellular test systems and their inherent 
variability, some extracts showed IC50 values slightly higher or lower than could have been 
predicted from the primary screen.  For direct comparison of activities it is therefore 
necessary to determine IC50 values by serial dilution (Appendix 1, Table 2.2, Page 109 - 111).  
This data, together with cytotoxicity data, helps to determine whether an activity is specific or 
just a generally toxic effect.  Extracts with favorable activities are followed up by HPLC-
based activity profiling [12].  We have recently developed and validated a microtiter-based 
protocol for the miniaturized and efficient identification of antiprotozoal compounds in 
extracts [10], and successfully applied this approach to the discovery of new antiprotozoal 
natural products in other library-based discovery projects [13-15].  Results from the profiling 
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In South Africa, Salvia repens is used traditionaly to treat sores, stomach ache and diarrhoea.  
The high performance liquid chromatography (HPLC)-based activity profiling of S. repens 
whole plant extract showed an active abietane diterpene, identified as 12-methoxycarnosic acid 
(P3-1) which showed antiprotozoal activity against axenically grown L. donovani amastigotes 
with an IC50 of 0.75 µM with marginal cytotoxicity against the L6-cells (IC50, 17.3 µM). 
 
Keywords: Antileishmanial activity; Salvia repens; Leishmania donovani; 12-methoxycarnosic 
acid; abietane diterpene; HPLC profiling 
 
Abbreviations: VL = Visceral leishmaniasis; HIV = Human Immunodeficiency virus; SANBI = 
South African National Biodiversity Institute; HPLC = high performance liquid chromatography; 
DMSO =dimethyl sulfoxide; PBS = phosphate buffer solution; FBS = fetal bovine serum; PDA 
=Photo Diode Array; NMR = Nuclear Magnetic Resonance; MS = Mass Spectrometry; SI = 




Visceral leishmaniasis (VL), also known as “Kala-azar” is caused by the intracellular protozoan 
Leishmania donovanii and is transmitted by the bite of infected phlebotomine sandflies.  It has 
been estimated that the annual global burden of VL is 500 000 new cases with more than 59 000 
associated deaths [1].  The control of VL relies entirely on chemotherapy due to the lack of 
antileishmanial vaccines.  In poor countries, however, the use of leishmanicidal drugs is 
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hampered by high costs, toxicity and the emergence of resistance [2].  In addition, the emergence 
of the Human Immunodeficiency virus/Acquired Immunodeficiency disease (HIV/AIDS) has 
severely compromised the control of VL [3].  Therefore, there is an urgent need for the 
development of new leishmanial therapeutics. 
 
The genus Salvia (sage) is the largest in the Lamiaceae family with over 900 species worldwide 
[4].  Approximately 30 Salvia species occur in southern Africa of which 26 are found in South 
Africa especially in the Cape region [5].  Salvia species are used in folk medicine for the 
treatment of asthma, eczema, psoriasis and tuberculosis [6].  In South Africa, Salvia species are 
used against fever, headache and digestive disorders [7], and to treat sores [8].  A decoction of 
the roots is also used in South Africa for the treatment of stomach ache and diarrhoea [8].  
Several kinds of tanshinone-type diterpenoids [9] abietane and icetexane diterpenoids and 
triterpenoic acids [4,10,11], phenolic acids, phenolic glycosides, flavonoids and anthocyanins 
[12] have been reported from Salvia species.  These constituents have shown various biological 
properties including antiviral [13], antiprotozoal [9,14,15] antimalarial [16] and antileishmanial 
[4] activities. 
 
In our previous study, the dichloromethane/methanol (1:1) extract of the whole plant of Salvia 
repens showed promising antiprotozoal activity with a IC50 value of 5.4 µg/ml against axenically 
grown Leishmania donovani amastigotes (MHOM/ET/67/L82) [17].  In this paper we report the 




Materials and methods 
Plant collection 
Salvia repens whole plant material was collected from the Eastern Cape Province near Aliwal-
North in January 2002.  The identification of plant material was done at the South African 
National Biodiversity Institute (SANBI, Pretoria) where thevoucher specimen (BP00998) was 
deposited.  The wet plant material was placed in an oven at 40 °C for three days to dry, then 
milled to a fine powder and kept at room temperature in the dark before extraction. 
 
Extract preparation 
Finely ground plant material of S. repens (100 g) was extracted with (2 × 1L) of a mixture of 
dichloromethane and methanol (1:1, v/v) overnight with occasional aggitation.  The mixture was 
filtered and concentrated using a rotavapour at 40 °C and left under a stream of cold air to dry. 
 
HPLC activity profiling 
The method described by Adams et al. [18] was used for the profiling of S. repens extract.  
Briefly, a 10 mg/ml sample in dimethyl sulfoxide (DMSO) was prepared, filtered through 0.45 
µm sterile filters for HPLC fractionation.  A Gilson 215 liquid handler with a Gilson 819 
injection module and 50 µl loop was used as the autosampler, connected to an HPLC system 
consisting of a 1100 series low-pressure mixing pump with degasser module, column oven, and a 
1100 series PDA detector (Agilent, Waldbronn, Germany).  The mobile system used was made 
up of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B).  Separation 
conditions: Sunfire RP-18 column (3.5 µm, 3 mm × 150 mm i.d.; Waters GmbH, Eschborn, 
Germany), water (A) 90-0% in acetonitrile (B) over 30 min, 100% acetonitrile (B) for 5 min.  
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The flow rate was 0.5 ml/min, and the injection volume was 35 µl (350 µg extract in DMSO).  
Thirty-five one-minute fractions were collected in 96 deep well plates during the run 
(Screenmates 96 well, Matrix Technology, Hudson, USA) and dried in a GeneVac EZ-2 Plus 
evaporator (Genevac Ltd., Ipswich, UK).  The samples were redissolved in 5 µl of DMSO and 
diluted with 95 µl phosphate buffer solution (PBS) buffer (137 mM NaCl, 10 mM phosphate, 2.7 
mM KCl, pH 7.4) for microfraction antileishmanial screening. 
 
In vitro antileishmanial activity evaluation of the microfractions and isolated compound 
The anti-leishmanial activity of the microfractions and isolated compound was evaluated by the 
method described by Adams et al. [18] at two different concentrations (5 µg/ml) and (0.8 µg/ml) 
against L. donovani amastigotes (MHOM/ET/67/L82) in a 96-well microtiter plate.  The plate 
was read in a spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Synnyvale, CA, USA) using an excitation wavelength of 536 nm and emission wavelength of 
588 nm.  Flouresence development was measured and expressed as a percentage of the control.  
The IC50 value was determined from the sigmoidal inhibition curve and miltefosine was used as 
a positive control. 
 
Cytotoxicity evaluations of 12-methoxycarnosic acid against L6-cells 
Assays were performed in 96-well microtiter plates, as previously discussed by Adams et al. 
[18].  The plates were incubated for 72 hours and thereafter inspected under an inverted 
microscope to assure growth of the controls and sterile conditions.  A volume of 10 µl of 
resazurin was then added to each well and the plates incubated for a further 2 hours.  The plates 
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were then evaluated as described above.  The IC50 value was calculated from the sigmoidal 
inhibition curve using SoftmaxPro software and podophylotoxin was used as a positive control. 
 
Isolation of the active compound 
The semi-preparative HPLC purification of the DCM/MeOH (1:1) crude extract of Salvia repens 
whole plant was performed with an HPLC 1200 series consisting of a low-pressure mixing pump 
with degasser module, a column oven and a PDA detector (Agilent, Waldbronn, Germany).  A 
100 mg/ml sample in DMSO was prepared and filtered through a 0.45 µm Millipore (Bedford, 
MA, USA) membrane filter and several repititions of 400 µl injections of the sample were made.  
The separation was performed on a Waters Sunfire RP-18 column (10 × 150 mm i.d.; 10 µm; 
Waters GmbH, Ireland).  The mobile system used was similar to that used for the HPLC activity 
profiling of the extract and made up of water (A) and acetonitrile (B).  The elution gradient was 
linear from A:B (90:10) to (0:100) in 30 min at a flow rate of 6.0 ml/min followed by washing 
and returning to the initial elution conditions (90:10) over 5 min.  The separation of the active 
component was detected at 280 nm.  The targeted fraction containing the compound of interest 
was collected and dried in a Genevac evaporator overnight to afford compound P3-1.  The 
structure of this compound was determined by 1H and 13C nuclear magnetic resonance (NMR) 
spectroscopyand mass spectrometry (MS) analysis as well as by comparison with the published 
data and was identified as 12-methoxycarnosic acid (P3-1) [19].  Using 800 mg of crude extract 




Results and discussion 
In our effort to identify potential antileishmanial compound/s from the DCM/MeOH (1:1) extract 
of Salvia repens whole plant, an analytical HPLC-based activity profiling technique [18] was 
used to fractionate the S. repens extract in a 96 deep-well microtiter plate.  The antileishmanial 
activity was in fraction 27 (figure 3.1).  The HPLC chromatogram at 280 nm depicted in figure 
3.1 made it possible to identify the active peak responsible for the observed antileishmanial 
activity.  Using semipreparative HPLC, 12-methoxycarnosic acid (P3-1), a known compound, 
was isolated and identified from its 1H and 13C NMR spectra (Appendix 2, Page 125 - 126) and 
by comparison of the NMR and MS data with that published in the literature [19] and its 
structure is indicated in figure 3.2.  The compound has been isolated previously from S. 






Figure 3.3 Antileishmanial activity trace of a DCM/MeOH (1:1) extract of the whole plant 
of Salvia repens fractions and UV trace (280 nm) of the one minute fractions tested against 




The antileishmanial activity of 12-methoxycarnosic acid (P3-1) was evaluated against axenic 
Leishmania donovani amastigotes and showed an IC50 value of 0.75 µM.  Miltefosine (the 
positive control) had an IC50 of 0.19 µM.  The selectivity index (SI), calculated as the ratio 
between IC50 value for cytotoxicity and IC50 value for L. donovani amastigotes for compound 










In recent years, the Lamiaceae plants of the genus Salvia have been extensively investigated for 
their biological and pharmacological properties.  Phytochemical studies of several Salvia species 
have led to the isolation of various phytochemical constituents mainly abietane diterpenoids such 
as carnosol, carnosic acid, rosemarinic acid [22] which have shown antioxidant [23] and 
cytotoxic [24] activities.  The antileishmanial [4] and antiplasmodial [25] activities of abietane 
diterpenoids have also been reported. 
Figure 3.4 The chemical structure of 12-methoxycarnosic acid (P3-1) isolated from the 
DCM/MeOH (1:1) extract of the whole plant of Salvia repens 
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Carnosic acid have shown to posses good peroxyl and hydroperoxyl radical scavenging activity, 
since it inhibits the formation of hydroxyl radicals and chelate metals and also scavenge H2O2 
[23].  In the other study, carnosic acid has been shown to inhibit lipid absorption [26].  Previous 
reports have shown that P3-1 has very interesting biological activities.  Murata and co-authors 
[27] reported that P3-1 resulted in a 66.7% binding inhibition of 5α-dihydrotestosterone (DHT) 
to the androgen receptor (AR) at 5 µM and the inhibition of 5α-reductase (IC50, 61.7 µM), 
thereby playing a significant role in promoting hair growth.  To the best of our knowledge this is 
the first report on the antileishmanial activity of 12-methoxycarnosic acid (P3-1). 
 
Conclusion 
The use of HPLC-based activity profiling made it possible to identify the active compound 
responsible for antileishmanial activity.  Compound (P3-1), 12-methoxycarnosic acid isolated 
from Salvia repens showed in vitro antileishmanial activity against axenic L. donovani 
amastigotes.  In addition, compound P3-1 has good selectivity.  Modifications to the structure of 
this compound could result in the development of new analogues with much more improved 
activity against this parasite. 
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Two hundred and seven extracts were prepared from sixty plants from South Africa and 
screened for in vitro activity against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, 
Leishmania donovani and Plasmodium falciparum.  For the 21 extracts which inhibited the 
growth of one or more parasites more than 95% at 10 µg/mL, the IC50 values against all four 
protozoal parasites and cytotoxic IC50 values against L6 myoblast were determined. Amongst 
the most notable results were the activities of Psoralea pinnata (IC50 of 0.15 µg/mL), 
Schkuhria pinnata (2.04 µg/mL) and Vernonia mespilifolia (1.01 µg/mL) against 
Trypansoma brucei rhodesiense. HPLC based activity profiling was used to identify the 
active constituents in the extracts, and the germacranolides sesquiterpene lactones schkuhrin I 
and II from Schkuhria pinnata, and cynaropicrin from Vernonia mespilifolia were identified, 
with IC50 values of 0.9, 1.5, and 0.23 µM, respectively. 
 
Keywords: Screening, plant extract library, antiprotozoal activity, sesquiterpene lactones, 
Asteraceae, Psoralea pinnata, Schkuhria pinnata, Vernonia mespilifolia, Trypansoma brucei 




Neglected tropical diseases (NTDs) caused by Leishmania species (leishmaniasis), 
Trypanosoma brucei rhodesiense (sleeping sickness) and Trypanosoma cruzi (Chagas 
disease) are life threatening and represent a risk to large parts of the populations in poor 
tropical countries.  These diseases affect almost 21.3 million people worldwide, mostly in 
economically challenged regions [1].  It is estimated that these three diseases are responsible 
for over 110,000 deaths every year [2].  In addition, malaria caused by Plasmodium species 
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was responsible for approximately 216 million infections and over 655,000 deaths in 2010 
[3].  The control of these parasitic infections relies on a few chemotherapeutic agents, most of 
which were discovered many decades ago [4] and pose many challenges due to adverse side 
effects, long treatment cycles, poor efficacy, high costs, the occurrence of drug resistances, 
and limited availability [1].  Therefore, the discovery of novel, safe and effective 
antiprotozoal agents is an urgent need. 
 
Natural products play a significant role in the discovery of new drug leads because of the 
unmatched availability of chemical diversity. We previously reported a screen of 300 extracts 
from plants traditionally used to treat malaria and their antiprotozoal effects against L. 
donovani, T. b. rhodesiense, P. falciparum and T. cruzi in vitro [5].  This work is a 
continuation of the project, where 207 further extracts have been tested.  Furthermore, we 
report the identification of three antitrypanosomal sesquiterpene lactones from the most 
active extracts, which were identified by HPLC based activity profiling [6].  
 
Materials and methods 
General experimental procedures 
 
Plant collection and identification 
Sixty plant species were collected between 1996 and 2002 at a variety of locations in South 
Africa.  The selected plant species were based on their traditional uses against parasitic 
diseases (unpublished work).  The species were identified by personnel of the South African 





Plant extract preparations 
The plant parts (roots, leaves, twigs, fruit, and stem bark) were dried in an oven at 30-60 ºC 
and extracts from finely ground plant parts were prepared as previously described [5].  Stock 
solutions were prepared at 10 mg/mL in DMSO and stored at -80 °C until use.  Dilutions for 
biological testing were freshly prepared in culture medium on the day of testing (< 1% 
DMSO). 
 
Isolation and purification of active compounds P4-1, P4-2, and P4-3 
For compounds P4-1, P4-2, and P4-3, semi-preparative HPLC purification was performed 
using an Agilent HPLC 1200 series consisting of a low-pressure mixing pump with degasser 
module, column oven, PDA detector (Agilent, Waldbronn, Germany).  The extract of the 
whole plant of Schkuhria pinnata (Lam.) Cabrera and Vernonia mespilifolia Less. (100 
mg/mL in DMSO, respectively) were prepared by dissolving 1.0 g of DCM/MeOH (1:1) 
extract, filtered through 0.45 µm Millipore (Bedford, MA, USA) membrane filters and 
several repetitions of 200 µL injections made.  The separation was performed on a Waters 
Sunfire RP-18 column (10 × 150 mm i.d.; 10 µm; Waters GmbH, Ireland).  The mobile 
system used was made up of water (A) and acetonitrile (B).  The elution gradient was linear 
from A:B (90:10) to (0:100) in 30 min at a flow rate of 6.0 mL/min, followed by 5 min 
acetonitrile washing and returned to the initial elution conditions (90:10) over 5 min.  The 
separation of all components was detected at a wavelength of 254 nm. 
 
Biological assays 
All extracts were screened as previously described [5] against P. falciparum (NF-54 strain), 
T. b. rhodesiense (STIB 900 strain), T. cruzi trypomastigote forms (Tulahuen strain), and L. 
donovani (strain MHOM/ET/67/L82) at 10 (high concentration) and 2 µg/mL (low 
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concentration).  Half maximal inhibition concentrations (IC50) were determined by serial 
dilution, and represent the mean of at least two independent experiments.  HPLC-based 
activity profiling was done as previously described [7].  Positive controls, melarsoprol (T. b. 
rhodesiense), benznidazole (T. cruzi), miltefosine (L. donovani), chloroquine (P. falciparum), 
and podophyllotoxin (L6 cells) were used.  The purity of all controls was > 95% according to 
the suppliers.  
 
In vitro test against Trypanosoma brucei rhodesiense 
Trypanosoma brucei rhodesiense (STIB 900) were grown in axenic medium as previously 
described [8].  The compounds were tested using a modified Alamar Blue assay protocol [9] 
to determine the 50% inhibitory concentration (IC50).  Serial three-fold drug dilutions were 
prepared in 96-well microtiter plates and 50 µL of T. b. rhodesiense STIB 900 bloodstream 
forms were added to each well except for the negative controls.  Melarsoprol (Arsobal®, 
Sanofi-Aventis, Meyrin, Switzerland) was used as a reference drug.  After 70 h of incubation 
Alamar blue marker (12.5 mg resazurin dissolved in 100 mL distilled water) was added.  The 
plates were then incubated for an additional 2 to 5 h.  A Spectramax Gemini XS micro plate 
fluorescence reader (Molecular Devices Cooperation, Sunnyvale, CA) with an excitation 
wavelength of 536 nm and an emission wavelength of 588 nm was used to read the plates.  
The IC50 values were calculated from the sigmoidal growth inhibition curves using Softmax 
Pro software (Molecular Devices). 
 
In vitro testing against Plasmodium falciparum 
A modification of the [3H]-hypoxanthine incorporation assay was used to determine the intra-
erythrocytic antiplasmodial activity [10] of the extract library and purified compounds in 96 
well plates.  Chloroquine (Sigma-Aldrich) and artesunate (Mepha, Switzerland) were used as 
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standard drugs.  Briefly, infected human red blood cells in RPMI 1640 medium (100 µL per 
well with 2.5% haematocrit and 0.3% parasitaemia) were exposed to two-fold serial drug 
dilutions in 96-well microtiter plates.  After 48 h incubation, 0.5 µCi [3H]-hypoxanthine was 
added to each well.  The plates were incubated for further 24 h before being harvested using a 
Betaplate cell harvester (Wallac, Zürich, Switzerland).  The radioactivity was counted with a 
Betaplate liquid scintillation counter (Wallac) as counts per minute per well at each drug 
concentration and compared to the untreated controls.  IC50 values were calculated from 
sigmoidal inhibition curves using Microsoft Excel.  All assays were run in duplicate and 
repeated three times [10].  
 
In vitro cytotoxicity testing 
Cytotoxicity was assessed using a similar Alamar Blue assay protocol [8] whereby 4000 rat 
myoblast cells/well were seeded in RPMI 1640 medium.  All following steps were according 
to the T.b.rhodesiense protocol.  Podophyllotoxin (Sigma-Aldrich) was used as the reference 
drug. 
 
Results and Discussion 
A total of 207 plants extracts from 67 plant species were assessed for antiprotozoal activity 
against four protozoan parasites at 10 and 2 µg/mL, respectively (Appendix 1, Table 4.1, 111 
- 122).  The most active extracts (≥ 95% parasitic growth inhibition) from the preliminary 
screening were subjected to the IC50 value determination study against the parasites which 
were most susceptible to.  Extracts which exhibited an IC50 value ≤ 5.0 µg/ml were 
considered active and were subjected to HPLC-based activity profiling technique to identify 
potential antiprotozoal compounds. The lipophillic extracts of Psoralea pinnata and Drypetes 
gerrardii exhibited very good antiprotozoal activity against T. b. rhodesiense (IC50, 0.15 ± 
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0.02 and 0.31 ± 0.02 µg/mL) and P. falciparum (IC50, 0.50 ± 0.23 µg/mL), respectively 
(Appendix 1, Table 4.2, Page 123 - 124).  In addition, these extracts showed the best 
selectivity index values ranging between 97 and 139 indicating their selectivity towards 
killing the parasites with very little toxicity towards the myoblasts L-6 cells.  Vernonia 
mespilifolia Less., Oedera genistifolia, Abrus precatorius africanus and Ekebergia capensis 
also exhibited IC50 values ranging between 1.0 and 1.7 µg/mL against T. b. rhodesiense and 
L. donovani, however, with moderate selectivity indices ranging from 24 to 48.  
 
The active extracts of Psoralea pinnata, Schkuhria pinnata and Vernonia mespilifolia were 
further studied to identify their active constituents.  For the purpose of this study we report 
the identification of active compounds from S. pinnata and V. mespilifolia by the aid of 
HPLC based activity profiling technique.  The one minute microfractions from the active 
DCM/MeOH extract from Schkuhria pinnata were tested against T. b. rhodesiense, and it was 
shown that the activity was concentrated in the active time windows of minutes 14 and 16 
(Figure 4.1), which showed 100 % inhibition.  These wells both contained one main 
substance, which were isolated by semi-preparative HPLC and structurally elucidated by 
NMR, high resolution MS, and comparison of spectral data to literature [11].  Fraction 14 
was shown to contain schkuhrin I (P4-1) and fraction 16, schkuhrin II (P4-2).  The two 
structurally similar germacranolides showed antiprotozoal activity against T. b. rhodesiense 
with IC50 values of 0.86 and 1.50 µM, respectively and antiplasmodial activity with IC50 




Table 4.3 Antiprotozoal activity (IC50 values in µM) of schkuhrin I (P4-1), schkuhrin II (P4-
2) and cynaropicrin (P4-3) against T. b. rhodesiense, T. cruzi, L. donovani and P. falciparum 
 
T. b. rhodesiense T. cruzi L. donovani P. falciparum Cytotox. L6 
IC50 SI IC50 SI IC50 SI IC50 SI IC50 
Schkuhrin I (P4-1) 0.86 6.12 16.4 0.32 39 0.13 2.05 2.57 5.26 
Schkuhrin II (P4-2) 1.50 6.02 26.96 0.33 65 0.14 1.67 5.41 9.03 
Cynaropicrin (P4-3) 0.23 5.61 5.14 0.25 1.56 0.83 1.56 0.83 1.29 
Melarsoprol 0.01 




      
Miltefosine 
    
0.47 
    
Chloroquine 




        
0.017 
 
The HPLC activity profile of the DCM/MeOH extract of V. mespilifolia showed significant 
antiprotozoal activity in fraction 12 and 13 against T. b. rhodesiense (Figure 4.2).  The major 
compound in these fractions was isolated and by use of NMR, high resolution MS and 
comparison to literature data [12] identified as the known sesquiterpene lactone cynaropicrin 
(P4-3).  The IC50 values of P4-3 were 0.23 µM against T. b. rhodesiense and 1.56 µM against 
P. falciparum. L. donovani exhibited an IC50 value of 1.56 µM whereas T. cruzi was the least 
























































Figure 4.2 HPLC-based activity profiling of Vernonia mespilifolia organic extract against T. b. 
rhodesiense. The bar graphs show the inhibitory activity of individual HPLC fractions collected 
from a single separation of the crude extract. The HPLC chromatogram was measured at 254 
nm. 
Figure 4.1 HPLC-based activity profiling of Schkuhria pinnata organic extract against T. b. 
rhodesiense. The bar graphs show the inhibitory activity of individual HPLC fractions collected 




























Figure 4.3 Structures of the isolated compounds, schkuhrin I (P4-1) and schkuhrin II (P4-2) 
from Schkuhria pinnata and cynaropicrin (P4-3) from Vernonia mespilifolia crude extracts 
 
This study is a continuation of our efforts of collecting and screening South African plants 
against protozoan parasites [5].  The results of a large screen of 207 extracts are shown 
(Appendix 1, Table 4.1, Page 112 - 123).  Furthermore, by using HPLC based activity 
profiling the sesquiterpene lactones schkuhrin I (P4-1) and II (P4-2) from Schkuhria pinnata, 
and cynaropicrin (P4-3) from Vernonia mespilifolia, were identified as potent antiprotozoal 
agents.  The powdered leaf of S. pinnata has been used as a remedy for malaria, influenza and 
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colds [13] as well as insecticides, and particularly to kill fleas [14].  Both schkuhrin I (P4-1) 
and II (P4-2) have been isolated from the same species and other Schkuhria species but their 
antiprotozoal activities especially against these parasites have not been reported previously.  
Some of the species belonging to the genus Vernonia have been used in folk medicine to treat 
malaria [15].  V. mespilifolia Less. is used traditionally by the Zulu population in South 
Africa to treat malaria related feverish conditions [16]. 
 
Sesquiterpenes are the largest known group of natural products [17] and are a chemical 
marker for the largest plant family, the Asteraceae [18].  Numerous sesquiterpene lactones 
have been tested for antiprotozoal activity in vitro.  Schmidt et al. [19] showed in an 
antitrypanosomal-QSAR study of 40 STLs, and in 2012 supplied two excellent reviews of 
antiprotozoal in vitro effects of 883 plant derived natural products including 83 sesquiterpene 
lactones [17, 20].  This study is the first report of the antiprotozoal effects of P4-1 and P4-2, 
whereas the antitrypansomal effects of P4-3 had already been described by Zimmermann et 
al. [7].  In fact, P4-3 was the first and so far the only plant derived compound to inhibit T. b. 
rhodesienese in vivo.  The mode of action of P4-3 was shown to be its ability to form stable 
bis-adducts with trypanothione via a Michael addition, thus depleting the parasites of their 
only means of redox control [21]. 
 
With this screening study we report recent in vitro results of a plant extract screen.  This may 
provide a basis for selecting plants in the future for further phytochemical and bioactivity 
studies.  Furthermore we report the in vitro antiprotozoal effects of three compounds, which 
will contribute to a better understanding of sesquiterpene lactones antiprotozoal structure- 
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In this study, over 507 extracts from 174 South African plant species used for the treatment of 
parasitic diseases, mainly malaria and associated symptoms such as fever were selected and 
screened in a medium throughput screen to identify and select active plant species for the 
isolation of active compounds with the potential to act against T. b. rhodesiense, T.cruzi, L. 
donovani and P. falciparum.  Of the plant species used in the study, 107 showed very promising 
antiprotozoal activities by exhibiting more than 95% growth inhibition against T. b. rhodesiense, 
T.cruzi, L. donovani and P. falciparum when tested at 10 µg/ml.  The antiprotozoal activities 
were quantified by subjecting the extracts of these plant species to IC50 and cytotoxicity 
determination assays, thereby determining not only their activity, but their selectivity as well, 
taking into account the toxicity of the compounds used in the bioassays.  Plants extracts with a 
very low selectivity index may not necessarily be good candidates for further isolation simply 
because the observed activity might be due to a general toxicity of the compounds contained in 
the extracts.  On the other hand, the active compound may not necessarily be the compound 
responsible for the toxicity of the extract.  Nevertheless, plants with a high selectivity index are 
more suited to phytochemical studies.  A library of South African plant species with potential 
antiprotozoal activity was thus identified from this work and would be available for those 
chemists wanting to undertake phytochemical studies in the search for lead compounds with 
antiprotozoal activity.  As a follow up study, Salvia repens, Schkuhria pinnata and Vernonia 
mespilifolia with selectivity indices of were chosen to be studied phytochemically and to isolate 




With the aid of the HPLC-based activity profiling technique, four active compounds (P3-1, P4-1, 
P4-2 and P4-3) were isolated from the extracts of Salvia repens, Schkuhria pinnata and 
Vernonia mespilifolia.  The isolated compounds and in particular, the sesquiterpene lactones 
showed very promising antiprotozoal activity against Trypanosoma brucei rhodesiense.  Of the 
four, cynaropicrin (P4-3) from the leaves of V. mespilifolia was the most active.  Toxicity studies 
against the rat skeletal myoblast cells indicated that these compounds are quite cytotoxic.  
Further work, such as structural modifications to these sesquiterpene lactones is important to 
determine whether the activity has to do with certain functional groups on the molecule and 
whether or not the molecule retains it acitivty, should the molecule be made less cytotoxic by the 
derivatisation of the functional groups. 
 
Further phytochemical work on other lead plants from this study can also be carried out either 
using conventional Natural Products Chemistry approaches or the HPLC-based activity profiling 




Table 4.1 Medium Throughput screening (MTS) results of 300 South African plants extracts against Trypanosoma brucei rhodesience, Trypanosoma cruzi, 
L. donovani and Plasmodium falciprum. Antiprotozoal activity reported in percentage (%) growth inhibition. 
 
     T. b. rhodesience T. cruzi L. donovani P. falciparum 








Family Species Voucher 
number 
















Acanthaceae Asystasia gangetica T.Anderson P05622b Twigs  DCM/MeOH (1:1) 5.6 0.0 0.0 0.0 27.5 0.0 39.5 3.3 
Fabaceae Acacia nilotica (L.) kraussianna P12859b Twigs  DCM/MeOH (1:1) 18.0 17.4 6.3 4.7 22.2 11.1 43.0 0.0 
Fabaceae Acacia nilotica (L.) kraussianna P12859c Twigs  Aqueous 6.2 9.4 9.9 1.3 18.2 2.2 0.0 0.0 
Fabaceae Acacia tortilis (Forssk) Hayne P12869b Whole plant DCM/MeOH (1:1) 16.7 4.3 12.4 3.3 27.9 6.7 58.9 4.3 
Amaranthaceae Achyranthes aspera L. P15190b Whole plant DCM/MeOH(1:1) 11.9 9.7 0.0 0.0 35.8 0.0 52.5 0.0 
Rutaceae Agathosma apiculata G.Mey. P09995b Whole plant DCM/MeOH (1:1) 99.1 0.0 0.0 0.4 72.9 14.2 80.1 21.4 
Rutaceae Agathosma puberula (Steud.) Forc. P02011a Roots DCM 98.4 7.4 0.0 0.0 67.5 8.5 57.6 1.0 
Rutaceae Agathosma puberula (Steud.) Forc. P02011b Roots DCM/MeOH (1:1) 0.0 1.3 0.0 0.0 29.4 0.8 33.8 0.7 
Rutaceae Agathosma puberula (Steud.) Forc. P02022a Stem bark DCM 3.0 8.0 10.3 2.2 52.5 5.3 94.6 9.3 
Rutaceae Agathosma puberula (Steud.) Forc. P02022b Stem bark DCM/MeOH (1:1) 4.6 0.0 3.9 0.0 17.3 4.2 25.0 14.4 
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     T. b. rhodesience T. cruzi L. donovani P. falciparum 








Family Species Voucher 
number 
















Asphodelaceae Ageratum conyzoides L. P12944b Whole plant DCM/MeOH(1:1) 3.6 0.9 9.4 3.4 27.0 16.6 36.2 0.0 
Asphodelaceae Ageratum conyzoides L. P12944c whole plant Aqueous 0.0 0.0 0.0 8.1 39.9 20.4 4.3 4.0 
Apiaceae Alepidea amatymbica Eckl. & Zeyh. P02873b Whole plant DCM/MeOH (1:1) 1.7 0.0 0.0 0.0 89.2 23.3 56.4 1.2 
Asphodelaceae Aloe ferox Mill. P01713a Fruits DCM 10.4 0.0 1.7 0.0 7.2 0.8 14.0 0.0 
Asphodelaceae Aloe ferox Mill. P01713b Fruits DCM/MeOH (1:1) 14.7 0.0 0.0 5.0 17.1 8.7 1.2 0.0 
Asphodelaceae Aloe ferox Mill. P01713c Fruits Aqueous 0.6 6.9 6.9 4.9 13.3 0.0 0.0 0.0 
Asphodelaceae Aloe ferox Mill. P03153b Whole plant DCM/MeOH (1:1) 8.6 4.0 0.0 0.0 41.6 11.4 59.0 5.0 
Asphodelaceae Aloe marlothii A.Berger P00054b Leaves DCM/MeOH (1:1) 13.4 9.6 0.0 0.0 5.2 0.0 0.0 3.9 
Asphodelaceae Aloe marlothii A.Berger P00054d Leaves Aqueous 15.4 8.5 0.0 0.0 21.5 9.2 3.1 0.0 
Asphodelaceae Aloe marlothii A.Berger P00770b Whole plant DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 21.0 2.4 15.8 0.6 
Annonaceae Annona senegalensis P01034b Leaves DCM/MeOH (1:1) 0.0 2.6 0.3 0.0 11.2 0.0 92.5 0.0 
Gentianaceae Anthocleista grandiflora Gilg P01455c Leaves Aqueous 0.0 2.5 0.0 0.0 16.6 3.3 2.2 0.0 
Gentianaceae Anthocleista grandiflora Gilg P01455a Leaves DCM 43.3 23.6 0.0 0.0 31.6 5.1 26.4 0.0 
Gentianaceae Anthocleista grandiflora Gilg P01455b Leaves DCM/MeOH (1:1) 18.0 20.6 0.0 0.0 20.4 16.0 2.4 0.0 
Annonaceae Artabotrys brachypetalus Benth. P02239b Twigs/Leaves DCM/MeOH (1:1) 3.5 6.1 0.0 0.0 16.3 11.5 17.3 2.7 
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Annonaceae Artabotrys brachypetalus Benth. P02239c Twigs/Leaves Aqueous 2.0 0.8 0.0 1.3 15.8 3.1 0.0 0.0 
Annonaceae Artabotrys monteiroae Oliv. P18314b Leaves DCM/MeOH (1:1) 99.4 0.0 9.2 7.9 25.0 5.2 40.5 0.0 
Annonaceae Artabotrys monteiroae Oliv. P18314c Leaves Aqueous 0.0 0.3 15.0 5.3 17.6 10.3 0.0 0.0 
Asteraceae Artemisia afra Jacq. ex Willd. P00484a Leaves DCM 98.2 0.0 0.0 0.0 100.0 25.9 89.5 8.0 
Asteraceae Artemisia afra Jacq. ex Willd. P00484b Leaves DCM/MeOH (1:1) 96.7 0.2 0.0 0.0 100.0 43.5 77.1 3.0 
Asteraceae Artemisia afra Jacq. ex Willd. P00484c Leaves MeOH 96.2 5.3 0.0 0.0 81.2 0.5 35.3 0.0 
Asparagaceae Asparagus virgatus Baker P08216b Whole plant DCM/MeOH(1:1) 10.5 9.2 0.0 10.9 34.6 14.1 54.9 3.2 
Acanthaceae Asystasia gangetica T.Anderson P05623b Leaves DCM/MeOH (1:1) 0.0 0.0 1.7 0.0 18.5 0.0 99.8 51.4 
Lecythidaceae Barringtonia racemosa (L.) Roxb. P15194c Leaves Aqueous 0.0 5.5 3.0 0.0 14.6 8.7 0.0 0.8 
Lecythidaceae Barringtonia racemosa (L.) Roxb. P15194b Leaves DCM/MeOH (1:1) 3.1 0.0 4.8 3.8 24.9 2.7 33.1 6.0 
Lecythidaceae Barringtonia racemosa (L.) Roxb. P15193b Twigs  DCM/MeOH (1:1) 31.6 5.3 6.5 2.0 26.1 0.0 26.6 0.0 
Apiaceae Berula erecta (Huds.) Coville P05646b Whole plant DCM/MeOH(1:1) 17.2 9.1 0.0 0.0 35.8 5.0 44.3 6.2 
Asteraceae Bidens pilosa L. P00071b Leaves DCM/MeOH (1:1) 20.3 21.3 0.0 0.0 25.9 14.4 42.9 15.2 
Asteraceae Bidens pilosa L. P00071c Leaves MeOH 21.2 17.1 0.0 0.0 37.2 13.8 47.3 4.9 
Asteraceae Bidens pilosa L. P00071d Leaves Aqueous 18.9 14.7 0.0 0.0 22.6 14.1 12.8 0.3 
Rhizophoraceae Bruguiera gymnorhiza (L.) Lam. P18322b Twigs  DCM/MeOH(1:1) 0.0 0.0 0.0 1.1 26.0 9.0 34.9 0.4 
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Capparaceae Capparis tomentosa Lam. P00665a Leaves DCM 29.8 23.8 0.0 0.0 39.4 6.7 4.9 0.0 
Capparaceae Capparis tomentosa Lam. P00667a Stem bark DCM 7.5 6.3 0.0 0.0 29.6 0.0 14.5 0.0 
Capparaceae Capparis tomentosa Lam. P00669a Roots DCM 5.2 5.7 0.0 0.0 17.7 9.4 0.0 3.9 
Capparaceae Capparis tomentosa Lam. P00665b Leaves DCM/MeOH (1:1) 5.7 0.0 0.0 0.0 18.8 0.0 21.4 0.0 
Capparaceae Capparis tomentosa Lam. P00667b Stem bark DCM/MeOH (1:1) 3.8 17.1 0.0 0.0 10.0 0.0 0.6 0.0 
Capparaceae Capparis tomentosa Lam. P00669b Roots DCM/MeOH (1:1) 22.2 3.0 0.0 0.0 32.3 3.8 0.0 0.0 
Apocynaceae Carissa edulis Vahl P00334a Stem bark DCM 0.0 6.1 0.0 0.0 36.1 12.1 27.7 3.0 
Apocynaceae Carissa edulis Vahl P00334b Stem bark DCM/MeOH (1:1) 8.7 7.0 0.0 0.0 32.9 7.5 14.2 0.0 
Apocynaceae Carissa edulis Vahl P00334c Stem bark MeOH 13.5 16.1 0.0 0.0 19.2 0.0 0.0 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00465a Seed DCM 0.0 0.0 0.0 0.0 33.3 10.4 36.5 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00465b Seed DCM/MeOH (1:1) 0.0 11.5 0.0 0.0 19.1 0.0 10.6 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00465c Roots MeOH 0.0 9.4 0.0 0.0 16.4 7.0 8.6 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00469a Roots DCM 57.1 9.7 0.0 0.0 100.0 23.2 99.4 8.8 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00469b Roots DCM/MeOH (1:1) 0.0 8.3 0.0 0.0 30.9 0.0 23.5 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00469c Leaves MeOH 2.8 3.1 0.0 0.0 9.2 3.5 17.9 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00470a Leaves DCM 5.2 0.0 0.0 0.0 20.8 0.0 29.5 0.0 
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Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00470b Leaves DCM/MeOH (1:1) 0.0 7.9 0.0 0.0 13.5 0.0 42.1 8.2 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00465d Seed Aqueous 0.0 7.4 2.8 2.1 5.9 4.5 0.0 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00469d Roots Aqueous 0.0 0.0 9.8 0.0 23.7 12.3 0.0 0.0 
Celastraceae Catha edulis (Vahl) Forssk. ex Endl. P00470d Leaves Aqueous 0.0 4.4 1.7 6.4 24.3 9.1 92.2 0.0 
Apiaceae Centella asiatica (L.) Urb. P05632b Leaves DCM/MeOH (1:1) 0.0 0.0 0.0 2.6 42.9 1.6 38.6 6.8 
Rutaceae Clausena anisata  P09997b Twigs  DCM/MeOH (1:1) 4.7 0.0 0.0 0.0 20.5 7.6 18.1 0.7 
Rutaceae Clausena anisata  P09998b Leaves DCM/MeOH (1:1) 4.8 0.0 3.9 0.0 30.9 2.8 24.9 0.0 
Euphorbiaceae Clutia hirsuta E.Mey. ex Sond. P11867b Whole plant DCM/MeOH (1:1) 8.0 3.9 0.0 0.9 40.1 11.8 68.9 10.2 
Euphorbiaceae Clutia hirsuta E.Mey. ex Sond. P11867c Whole plant Aqueous 25.6 15.2 1.3 0.0 20.3 9.1 0.0 0.0 
Combretaceae Combretum zeyheri Sond. P13042b Twigs  DCM/MeOH (1:1) 9.5 0.0 47.3 0.0 25.8 4.4 33.4 0.0 
Combretaceae Combretum zeyheri Sond. P13042c Twigs  Aqueous 7.0 0.0 0.0 0.0 10.8 6.9 19.0 0.0 
Asteraceae Conyza albida Spreng. P12954b Whole plant DCM/MeOH (1:1) 99.9 0.0 0.0 2.8 62.8 9.7 97.3 6.2 
Asteraceae Conyza albida Spreng. P12954c whole plant Aqueous 0.0 3.5 0.0 1.3 21.2 11.2 1.0 0.0 
Asteraceae Conyza podocephala DC. P03063b Whole plant DCM/MeOH (1:1) 6.4 4.5 0.0 0.0 53.2 4.0 98.6 12.4 
Asteraceae Conyza scabrida DC. P03168b Flowers/Buds DCM/MeOH (1:1) 1.7 6.0 0.0 0.0 93.0 11.9 59.6 0.0 
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Asteraceae Conyza scabrida DC. P03169b Twigs  DCM/MeOH (1:1) 1.8 15.3 0.0 0.0 45.4 17.8 40.8 0.0 
Asteraceae Conyza scabrida DC. P03170b Leaves DCM/MeOH (1:1) 0.0 2.6 0.0 0.0 100.0 4.8 52.6 7.2 
Amaryllidaceae Crinum macowanii Baker  P05637b Flowers/Buds DCM/MeOH (1:1) 51.6 25.8 1.2 3.4 36.0 5.5 46.8 0.0 
Amaryllidaceae Crinum macowanii Baker  P05637c Flowers/Buds Aqueous 0.0 0.0 0.0 0.0 2.1 0.0 1.6 0.0 
Fabaceae Crotalaria burkeana Benth. P00417b Roots DCM/MeOH (1:1) 25.4 9.2 0.0 0.0 22.3 5.2 20.5 0.0 
Fabaceae Crotalaria burkeana Benth. P00418b Seed DCM/MeOH (1:1) 18.0 7.7 0.0 0.0 63.0 10.4 65.6 5.3 
Fabaceae Crotalaria burkeana Benth. P00417c Leaves MeOH 6.2 4.6 0.0 0.0 28.9 9.1 4.7 0.0 
Fabaceae Crotalaria burkeana Benth. P00417d Leaves Aqueous 11.2 7.1 0.0 0.0 22.6 0.0 0.0 0.0 
Fabaceae Crotalaria burkeana Benth. P00418d Roots Aqueous 6.8 3.2 0.0 0.0 21.9 6.7 0.0 0.0 
Euphorbiaceae Croton gratissimus P00010c Leaves MeOH 14.1 13.0 0.0 0.0 31.2 4.7 23.9 13.1 
Euphorbiaceae Croton gratissimus  P00010d Leaves Aqueous 4.4 17.3 0.0 0.0 10.4 3.2 0.0 0.0 
Euphorbiaceae Croton menyhartii Pax P12951b Leaves DCM/MeOH (1:1) 98.6 2.1 8.1 0.0 65.6 6.7 100.0 27.4 
Euphorbiaceae Croton menyhartii Pax P12952b Twigs  DCM/MeOH (1:1) 97.9 10.2 0.1 1.5 55.9 20.1 100.1 32.8 
Euphorbiaceae Croton menyhartii Pax P12951c Leaves Aqueous 16.2 7.2 0.0 12.3 28.5 16.8 3.6 0.0 
Euphorbiaceae Croton menyhartii Pax P12952c Twigs  Aqueous 3.8 4.9 0.0 2.8 27.9 25.6 1.0 0.0 
Araliaceae Cussonia spicata Thunb. P00042a Roots DCM 12.1 12.9 0.0 0.0 31.4 4.4 28.2 0.0 
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Araliaceae Cussonia spicata Thunb. P00042c Leaves MeOH 14.7 7.0 0.0 0.0 91.8 15.6 17.0 1.6 
Araliaceae Cussonia spicata Thunb. P02612b Leaves DCM/MeOH (1:1) 1.6 5.8 10.7 2.5 68.0 5.6 70.8 12.2 
Poaceae Cymbopogon validus  P12881b Whole plant DCM/MeOH (1:1) 98.7 6.2 5.7 5.9 40.8 7.3 97.5 7.0 
Rutaceae  Diosma sp (exact species not identified) P02051b Roots DCM/MeOH (1:1) 10.0 3.1 0.0 0.0 17.5 0.0 13.8 0.0 
Rutaceae Diosma sp(exact species not identified) P02051a Roots DCM 17.4 13.3 0.8 0.4 68.8 14.6 93.3 17.0 
Apocynaceae Diplorhynchus condylocarpon  P00940b Roots DCM/MeOH (1:1) 0.0 5.6 0.0 0.0 19.3 0.0 4.1 2.9 
Sapindaceae Dodonaea viscosa Jacq. P02291b Leaves DCM/MeOH (1:1) 1.5 1.4 5.2 5.1 65.0 14.4 32.5 0.0 
Meliaceace Ekebergia capensis Sparrm. P03111b Fruits DCM/MeOH (1:1) 99.4 11.9 0.0 0.0 96.4 20.4 81.3 17.4 
Meliaceace Ekebergia capensis Sparrm. P03112b Twigs  DCM/MeOH (1:1) 58.0 0.0 0.0 0.0 67.8 6.7 44.0 4.0 
Meliaceace Ekebergia capensis Sparrm. P03111c Fruits Aqueous 0.0 0.0 0.0 0.0 10.3 1.2 0.0 0.0 
Fabaceae Elephantorrhiza elephantina  P08224c roots Aqueous 41.2 20.1 18.4 0.0 29.3 20.3 6.1 0.0 
Fabaceae Elephantorrhiza elephantina  P08225c Leaves Aqueous 7.4 11.9 0.0 0.9 21.8 7.3 3.5 0.0 
Fabaceae Elephantorrhiza elephantina (Burch.)  P08224b Roots DCM/MeOH (1:1) 0.0 2.5 0.0 0.0 31.6 2.9 22.6 0.0 
Fabaceae Elephantorrhiza elephantina (Burch.)  P08224b Leaves DCM/MeOH (1:1) 2.3 0.0 0.0 3.2 27.0 5.6 34.8 0.0 
Ebenaceae Euclea natalensis A.DC. P08226b Stem bark DCM/MeOH (1:1) 4.4 0.1 0.0 0.0 53.1 0.0 40.4 0.0 
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Ebenaceae Euclea natalensis A.DC. P08227b Roots DCM/MeOH (1:1) 98.4 0.0 0.0 0.0 42.7 0.0 79.8 17.1 
Ebenaceae Euclea undulata Thunb. P09984b Leaves DCM/MeOH (1:1) 0.0 0.0 0.0 3.7 57.7 6.3 39.2 0.0 
Ebenaceae Euclea undulata Thunb. P09985b Twigs  DCM/MeOH (1:1) 4.0 0.0 6.8 5.3 34.9 5.2 65.7 0.0 
Hyacinthaceae Eucomis autumnalis (Mill.) Chitt. P01463a Flowers/Buds DCM 2.5 0.0 0.0 0.0 95.5 33.4 22.8 2.4 
Hyacinthaceae Eucomis autumnalis (Mill.) Chitt. P01463b Flowers/Buds DCM/MeOH (1:1) 7.3 9.1 55.1 0.0 28.8 7.3 2.8 0.0 
Hyacinthaceae Eucomis autumnalis (Mill.) Chitt. P01463c Flowers/Buds Aqueous 18.5 19.0 0.0 0.0 15.8 7.8 0.0 0.0 
Euphorbiaceae Euphorbia heterophylla L. P12864b Whole plant DCM/MeOH (1:1) 6.6 7.3 0.0 0.7 30.4 6.0 40.8 7.2 
Euphorbiaceae Euphorbia tirucalli L. P00788a Leaves DCM 86.5 0.0 0.0 0.0 43.7 8.2 60.3 0.0 
Euphorbiaceae Euphorbia tirucalli L. P00788b Leaves DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 22.3 0.0 15.4 2.9 
Euphorbiaceae Euphorbia tirucalli L. P00788c Leaves MeOH 18.7 21.3 3.9 5.9 28.7 2.4 0.0 0.0 
Flacourtiaceae Flacourtia indica (Burm.f.) Merr. P00904a Roots DCM 0.0 0.9 0.0 0.0 10.6 1.8 9.3 0.0 
Flacourtiaceae Flacourtia indica (Burm.f.) Merr. P00904c Roots Aqueous 11.4 4.6 0.0 0.0 10.8 0.0 0.3 0.4 
Colchicaceae Gloriosa superba L. P08215b Whole plant DCM/MeOH (1:1) 7.5 9.2 26.7 0.0 24.9 13.1 43.6 11.4 
Colchicaceae Gloriosa superba L. P08215c whole plant Aqueous 0.0 17.1 23.4 0.0 12.5 4.5 0.0 0.0 
Apocynaceae Gomphocarpus fruticosus (L.) Aiton.f. P09988b Fruits DCM/MeOH(1:1) 1.4 0.0 7.4 0.0 21.7 14.3 5.3 0.0 
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Apocynaceae Gomphocarpus fruticosus (L.) Aiton.f. P09989b Leaves DCM/MeOH(1:1) 9.1 0.6 2.9 2.9 21.4 11.2 22.7 0.0 
Asteraceae Helichrysum nudifolium. P02847b Whole plant DCM/MeOH (1:1) 0.0 10.7 0.0 0.0 99.9 14.0 63.2 3.2 
Sapindaceae Hippobromus pauciflorus (L.f.) Radlk. P12876b Leaves DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 32.0 15.4 58.6 0.0 
Sapindaceae Hippobromus pauciflorus (L.f.) Radlk. P12876c Leaves Aqueous 13.8 0.8 0.6 0.0 15.4 3.8 0.0 0.0 
Sapindaceae Hippobromus pauciflorus (L.f.) Radlk. P12877b Twigs  DCM/MeOH (1:1) 4.2 7.5 2.5 0.0 73.2 6.0 90.9 13.1 
Clusiaceae Hypericum aethiopicum Thunb. P02817b Leaves DCM/MeOH (1:1) 98.8 75.1 5.9 2.7 100.0 55.2 100.0 32.9 
Clusiaceae Hypericum aethiopicum Thunb. P02817c Leaves Aqueous 0.0 4.7 0.0 0.0 14.6 1.7 0.0 5.1 
Lamiaceae Hyptis pectinata (L.) Poit.  P02459b Leaves DCM/MeOH (1:1) 0.0 2.4 26.7 0.0 37.1 6.3 34.2 0.0 
Lamiaceae Hyptis pectinata (L.) Poit.  P02459c Twigs/Leaves Aqueous 8.8 0.7 2.2 2.8 31.5 26.9 6.8 0.6 
Acanthaceae Justicia flava  P05636b Whole plant DCM/MeOH (1:1) 0.0 11.8 0.0 0.0 11.9 0.0 21.0 0.0 
Bignoniaceae Kigelia africana (Lam.) Benth. P00692a Leaves DCM 11.5 12.0 0.0 0.0 32.7 3.0 6.3 0.0 
Bignoniaceae Kigelia africana (Lam.) Benth. P00692b Leaves DCM/MeOH (1:1) 14.7 4.2 0.0 0.0 9.5 9.2 6.1 0.0 
Kirkiaceae  Kirkia wilmsii Engl. P13041c Leaves Aqueous 0.0 0.0 0.0 0.0 18.4 7.4 60.9 0.0 
Lamiaceae Leonotis leonurus (L.) R.Br. P03268b Twigs  DCM/MeOH (1:1) 3.1 12.9 0.0 0.0 48.3 0.0 85.7 7.5 
Lamiaceae Leonotis leonurus (L.) R.Br. P03269b Leaves DCM/MeOH (1:1) 32.1 9.1 0.0 0.0 85.0 4.8 81.4 16.3 
Lamiaceae Leonotis leonurus (L.) R.Br. P02414c roots Aqueous 7.3 8.2 1.0 1.4 32.3 26.3 7.6 0.0 
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Lamiaceae Leonotis leonurus (L.) R.Br. P03268c Twigs  Aqueous 5.3 0.0 0.0 0.7 12.2 2.4 0.0 0.0 
Lamiaceae Leonotis leonurus (L.) R.Br. P03269c Leaves Aqueous 17.1 0.0 0.0 0.0 13.1 3.2 0.0 0.0 
Lamiaceae Leonotis ocymifolia  P14867b Whole plant DCM/MeOH (1:1) 98.5 14.5 0.0 0.0 35.5 5.1 38.6 0.0 
Lamiaceae Leonotis ocymifolia  P00480d Leaves Aqueous 6.5 6.8 4.5 6.8 15.8 1.0 0.0 0.0 
Lamiaceae Leonotis ocymifolia  P00481d Fruits Aqueous 0.0 3.1 0.0 0.0 25.5 9.9 0.0 0.2 
Lamiaceae Leonotis ocymifolia  P00482c Roots MeOH 0.9 2.5 0.0 0.0 13.6 0.0 1.0 0.0 
Lamiaceae Leonotis ocymifolia  P00482d Roots Aqueous 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00480a Leaves DCM 99.6 12.9 0.0 0.0 54.4 10.2 74.4 9.3 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00480b Leaves DCM/MeOH (1:1) 99.1 22.3 0.0 0.0 60.0 8.9 81.0 0.5 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00480c Leaves MeOH 19.6 26.6 0.0 0.0 46.4 10.7 66.0 4.4 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00481a Fruits DCM 13.2 12.9 0.0 0.0 49.4 8.4 35.7 3.4 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00481b Fruits DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 36.1 3.7 6.9 0.0 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00481c Fruits MeOH 0.1 0.4 0.6 0.0 20.6 8.0 5.8 0.0 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00482a Roots DCM 20.3 10.6 0.0 0.0 36.7 0.0 21.7 0.0 
Lamiaceae Leonotis ocymifolia var. ocymifolia  P00482b Roots DCM/MeOH (1:1) 14.0 4.8 0.0 0.0 5.4 0.0 9.1 0.0 
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Lamiaceae Leucas martinicensis (L.) R.Br. P12950b Whole plant DCM/MeOH (1:1) 90.7 19.2 3.6 11.8 53.1 12.5 83.8 10.2 
Lamiaceae Leucas martinicensis (L.) R.Br. P12950c whole plant Aqueous 8.9 6.3 5.9 8.3 29.9 19.9 1.7 0.0 
Rutaceae Macrostylis squarrosa  P02402b Stem bark DCM/MeOH (1:1) 8.0 7.0 0.0 0.0 41.3 0.0 78.6 12.6 
Maesaceae Maesa lanceolata Forssk. P12946c Twigs  Aqueous 0.0 0.0 7.8 5.7 26.5 18.9 5.7 4.1 
Celastraceae Maytenus senegalensis (Lam.) Exell. P00690a Roots DCM 13.6 2.0 0.0 0.0 27.7 7.8 35.2 0.0 
Celastraceae Maytenus senegalensis (Lam.) Exell. P00693a Stem bark DCM 0.0 6.0 0.0 0.0 24.1 0.0 25.1 0.5 
Celastraceae Maytenus senegalensis (Lam.) Exell. P00693b Stem bark DCM/MeOH (1:1) 10.5 10.5 0.0 0.0 19.5 0.0 4.6 0.0 
Celastraceae Maytenus senegalensis (Lam.) Exell. P00693d Stem bark Aqueous 0.0 1.5 1.9 0.0 10.0 0.0 0.0 0.0 
Celastraceae Maytenus undata (Thunb.) Blakelock P00151b Leaves DCM/MeOH (1:1) 0.0 12.4 0.0 0.0 46.0 4.9 23.7 18.3 
Celastraceae Maytenus undata (Thunb.) Blakelock P00152a Stem bark DCM 17.7 13.4 3.4 0.0 83.4 17.0 25.9 5.2 
Celastraceae Maytenus undata (Thunb.) Blakelock P00152b Stem bark DCM/MeOH (1:1) 0.0 1.6 0.0 0.0 53.7 9.5 11.3 5.8 
Celastraceae Maytenus undata (Thunb.) Blakelock P00153a Roots DCM 0.8 5.8 0.0 0.0 98.7 30.2 42.4 0.3 
Celastraceae Maytenus undata (Thunb.) Blakelock P00153b Roots DCM/MeOH (1:1) 6.5 6.8 0.0 0.0 82.0 15.9 17.0 0.0 
Celastraceae Maytenus undata (Thunb.) Blakelock P00153c Roots MeOH 0.0 1.9 0.0 0.0 28.7 2.2 5.4 0.0 
Celastraceae Maytenus undata (Thunb.) Blakelock P00151c Leaves MeOH 4.2 7.0 0.0 0.0 18.8 3.6 13.8 9.4 
Celastraceae Maytenus undata (Thunb.) Blakelock P00152c Stem bark MeOH 0.0 1.6 3.7 2.5 38.7 14.3 6.1 0.0 
Celastraceae Maytenus undata (Thunb.) Blakelock P00151a Leaves DCM 2.8 9.4 0.0 0.0 41.2 0.0 8.3 0.0 
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Celastraceae Maytenus undata (Thunb.) Blakelock P00151d Leaves Aqueous 2.7 0.0 9.1 9.3 17.0 0.2 0.0 0.0 
Celastraceae Maytenus undata (Thunb.) Blakelock P00152d Stem bark Aqueous 0.0 0.0 13.1 2.9 16.1 10.9 0.0 0.0 
Celastraceae Maytenus undata (Thunb.) Blakelock P00153d Roots Aqueous 8.6 0.0 14.2 3.6 20.4 12.6 0.0 0.0 
Cucurbitaceae Momordica balsamina L. P04038b Stem bark DCM/MeOH (1:1) 2.2 0.5 0.0 0.0 33.6 2.6 83.4 17.0 
Cucurbitaceae Momordica balsamina L. P04039b Leaves DCM/MeOH (1:1) 21.2 22.7 0.0 0.0 49.2 7.8 64.7 4.5 
Lamiaceae Ocimum americanum L.  P12866b Whole plant DCM/MeOH (1:1) 0.0 4.3 0.0 0.0 30.2 2.5 100.1 0.1 
Oleaceae Olea europaea L.  P12848b Leaves DCM/MeOH (1:1) 55.2 0.0 14.5 5.8 52.0 8.4 46.3 0.0 
Oleaceae Olea europaea L.  P12849b Twigs  DCM/MeOH (1:1) 46.4 0.0 9.9 3.9 43.8 13.0 50.5 0.0 
Asteraceae Osteospermum imbricatum L. P02640b Stem bark DCM/MeOH (1:1) 7.4 12.9 3.5 1.8 51.4 2.6 92.9 3.0 
Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00253a Leaves DCM 0.0 3.5 0.0 0.0 66.9 21.7 53.0 0.0 
Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00253b Leaves DCM/MeOH (1:1) 18.7 4.7 0.0 0.0 26.0 0.0 9.1 0.0 
Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00253c Leaves MeOH 0.0 1.2 0.0 0.0 11.3 0.0 0.0 0.0 
Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00253d Leaves Aqueous 0.0 7.8 0.0 0.0 17.4 6.7 3.3 0.0 
Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00254b Roots DCM/MeOH (1:1) 0.0 11.8 0.0 0.0 26.9 11.0 22.7 0.0 
Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00254c Roots MeOH 13.7 8.5 0.0 0.0 23.3 13.6 11.7 0.0 
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Chrysobalanaceae Parinari curatellifolia Planch. ex Benth. P00254d Roots Aqueous 8.9 6.6 0.0 0.0 13.9 2.4 0.0 1.7 
Fabaceae Parkinsonia aculeata L. P09990b Twigs  DCM/MeOH (1:1) 5.8 1.6 0.0 2.8 26.3 3.0 32.3 0.0 
Gentianaceae Pelargonium alchemilloides (L.) L'Hér. P08205b Whole plant DCM/MeOH (1:1) 6.8 11.4 0.5 0.0 33.0 8.1 87.3 10.4 
Asteraceae Pentzia globosa Less. P01514a Leaves DCM 91.3 0.0 6.9 0.0 84.2 1.9 62.5 7.9 
Asteraceae Pentzia globosa Less. P01514b Leaves DCM/MeOH (1:1) 0.0 0.0 0.0 3.3 26.3 0.3 39.2 0.0 
Asteraceae Pentzia globosa Less. P01514c Leaves Aqueous 9.2 0.0 2.4 0.0 25.2 4.1 5.7 14.9 
Asteraceae Pentzia globosa Less. P01516a Roots DCM 99.1 6.5 9.8 9.4 63.2 18.4 96.0 20.8 
Asteraceae Pentzia globosa Less. P01516b Roots DCM/MeOH (1:1) 98.0 3.4 4.1 1.0 35.9 0.0 61.5 7.2 
Asteraceae Pentzia globosa Less. P01517a Stem bark DCM 98.9 0.0 7.7 0.0 33.9 12.2 76.1 5.3 
Asteraceae Pentzia globosa Less. P01517b Stem bark DCM/MeOH (1:1) 99.6 0.0 0.0 0.0 16.0 0.0 29.6 0.0 
Fabaceae Piliostigma thonningii  P18548c Fruits Aqueous 16.6 2.8 1.0 0.0 20.0 5.2 0.0 0.0 
Fabaceae Piliostigma thonningii  P18547c Leaves Aqueous 24.3 26.5 0.0 0.0 20.8 8.3 5.8 0.0 
Fabaceae Piliostigma thonningii  P18549c Twigs  Aqueous 18.9 6.4 3.5 0.0 22.4 2.7 0.0 0.0 
Pittosporaceae Pittosporum viridiflorum Sims P00213b Whole plant DCM/MeOH (1:1) 49.8 10.7 0.0 0.0 28.6 11.2 59.4 3.2 
Pittosporaceae Pittosporum viridiflorum Sims P00213c Whole plant MeOH 0.0 3.9 0.0 2.3 14.8 8.9 14.6 0.0 
Pittosporaceae Pittosporum viridiflorum Sims P00215a Leaves DCM 7.0 5.5 0.0 0.0 31.0 6.8 25.2 2.8 
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Pittosporaceae Pittosporum viridiflorum Sims P00215b Leaves DCM/MeOH (1:1) 1.4 0.1 0.0 0.0 4.4 0.0 0.0 0.0 
Pittosporaceae Pittosporum viridiflorum Sims P00215c Leaves MeOH 0.0 4.9 0.0 0.0 23.3 9.0 0.0 0.0 
Plantaginaceae Plantago major L. P01571b Whole plant DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 17.8 5.4 16.5 0.9 
Plumbaginaceae Plumbago zeylanica L. P00630a Roots DCM 20.5 19.4 0.0 0.0 19.5 0.0 16.1 0.0 
Plumbaginaceae Plumbago zeylanica L. P00630b Roots DCM/MeOH (1:1) 10.9 9.0 0.0 0.0 7.5 0.0 18.7 0.0 
Plumbaginaceae Plumbago zeylanica L. P00630c Roots MeOH 18.7 8.7 0.0 0.0 11.9 0.0 0.0 10.5 
Plumbaginaceae Plumbago zeylanica L. P00631b Leaves DCM/MeOH (1:1) 97.4 7.8 0.0 0.0 32.1 2.2 31.6 8.1 
Illecebraceae Pollichia campestris Aiton P00390b Leaves DCM/MeOH (1:1) 0.0 8.0 6.1 2.7 24.6 2.8 22.5 0.0 
Illecebraceae Pollichia campestris Aiton P00390c Leaves MeOH 18.0 9.4 0.0 0.0 18.3 5.9 0.0 0.0 
Illecebraceae Pollichia campestris Aiton P00391a Fruits DCM 4.0 0.0 0.0 0.0 41.7 6.3 57.7 0.0 
Illecebraceae Pollichia campestris Aiton P00391b Fruits DCM/MeOH (1:1) 3.5 8.1 0.0 0.0 21.8 5.8 6.9 0.0 
Illecebraceae Pollichia campestris Aiton P00391c Leaves MeOH 12.7 16.0 0.0 0.0 27.1 2.2 2.6 0.0 
Illecebraceae Pollichia campestris Aiton P03065b Whole plant DCM/MeOH (1:1) 9.3 9.7 0.0 0.0 51.0 0.0 83.8 8.5 
Illecebraceae Pollichia campestris Aiton P00390d Leaves Aqueous 0.0 0.0 0.0 0.0 16.1 6.3 0.0 0.0 
Illecebraceae Pollichia campestris Aiton P03065c whole plant Aqueous 0.0 0.0 0.0 0.0 14.8 0.0 0.0 0.3 
Illecebraceae Pollichia campestris Aiton P03318c Twigs  Aqueous 19.4 0.0 0.0 0.6 17.1 1.9 0.0 0.0 
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Asteraceae Psiadia punctulata  P00819b Leaves DCM/MeOH (1:1) 18.8 3.2 0.0 0.0 47.7 8.2 34.9 3.7 
Asteraceae Psiadia punctulata  P02527b Whole plant DCM/MeOH (1:1) 24.0 0.0 10.0 3.6 47.9 8.3 48.7 0.0 
Ptaeroxylaceae Ptaeroxylon obliquum (Thunb.) Radlk. P01842a Roots DCM 10.5 12.9 9.0 4.7 35.3 0.9 44.4 1.0 
Ptaeroxylaceae Ptaeroxylon obliquum (Thunb.) Radlk. P01842b Roots DCM/MeOH (1:1) 4.9 11.8 9.6 0.0 44.7 12.4 56.7 4.5 
Ptaeroxylaceae Ptaeroxylon obliquum (Thunb.) Radlk. P01870a Leaves DCM 99.7 0.0 0.0 0.0 55.0 5.5 41.3 5.4 
Ptaeroxylaceae Ptaeroxylon obliquum (Thunb.) Radlk. P01870b Leaves DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 19.1 2.4 24.2 0.0 
Ptaeroxylaceae Ptaeroxylon obliquum (Thunb.) Radlk. P01890a Stem bark DCM 10.1 0.0 0.0 0.0 52.7 1.4 79.8 17.3 
Ptaeroxylaceae Ptaeroxylon obliquum (Thunb.) Radlk. P01890b Stem bark DCM/MeOH (1:1) 30.1 4.6 0.0 0.0 40.3 4.2 65.4 12.8 
Fabaceae Pterocarpus angolensis DC. P00304b Stem bark DCM/MeOH (1:1) 0.0 6.6 0.0 0.0 17.4 8.8 0.2 0.0 
Fabaceae Pterocarpus angolensis DC. P00304c Stem bark MeOH 6.5 6.4 0.0 0.0 16.2 6.2 0.7 1.0 
Fabaceae Pterocarpus angolensis DC. P00305b Roots DCM/MeOH (1:1) 18.3 0.0 0.0 0.0 20.9 5.3 16.8 0.0 
Fabaceae Pterocarpus angolensis DC. P00305c Roots MeOH 16.3 1.6 0.0 0.0 11.8 0.4 0.0 0.0 
Apocynaceae Rauvolfia caffra Sond. P00734a Roots DCM 99.7 7.6 0.0 3.1 2.7 0.4 44.6 0.0 
Apocynaceae Rauvolfia caffra Sond. P00734b Fruits DCM/MeOH (1:1) 4.9 9.0 0.0 0.0 24.0 1.2 19.9 4.2 
Apocynaceae Rauvolfia caffra Sond. P00735b Roots DCM/MeOH (1:1) 6.5 0.0 0.0 0.0 15.0 1.5 9.5 0.0 
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Apocynaceae Rauvolfia caffra Sond. P00735d Roots Aqueous 5.7 6.7 0.0 0.0 13.0 0.0 0.0 0.0 
Apocynaceae Rauvolfia caffra Sond. P00735a Fruits DCM 13.1 16.0 0.0 0.6 19.7 7.6 15.4 0.0 
Euphorbiaceae Ricinus communis L. var. communis P02300b Leaves DCM/MeOH (1:1) 0.0 4.4 0.0 0.0 62.7 0.8 55.9 9.5 
Euphorbiaceae Ricinus communis L. var. communis P02311b Fruits DCM/MeOH (1:1) 5.3 1.4 0.0 0.0 6.9 0.0 12.9 0.0 
Euphorbiaceae Ricinus communis L. var. communis P02355b Stem bark DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 46.4 0.0 78.7 13.8 
Euphorbiaceae Ricinus communis L. var. communis P02300c Leaves Aqueous 6.9 2.3 10.9 0.9 34.6 22.0 2.4 6.7 
Euphorbiaceae Ricinus communis L. var. communis P02311c Fruits Aqueous 8.1 5.1 9.8 0.1 40.1 27.2 6.9 0.0 
Euphorbiaceae Ricinus communis L. var. communis P02355c Stem bark Aqueous 4.9 9.8 0.0 0.0 38.1 27.6 7.0 0.0 
Polygonaceae Rumex crispus L. P01689b Roots DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 20.1 7.9 21.0 4.8 
Polygonaceae Rumex crispus L. P01634a Leaves DCM 2.1 0.0 0.0 0.0 11.6 3.7 9.7 2.4 
Polygonaceae Rumex crispus L. P01634b Leaves DCM/MeOH (1:1) 0.0 3.6 0.0 0.0 18.7 0.4 0.1 0.0 
Polygonaceae Rumex crispus L. P01689a Roots DCM 0.9 3.6 0.0 0.0 28.0 5.4 55.3 5.0 
Polygonaceae Rumex sagittatus Thunb. P12875b Whole plant DCM/MeOH (1:1) 6.7 0.0 4.0 0.0 18.5 3.6 38.4 0.0 
Lamiaceae Salvia repens Burch. ex Benth. P08214b Whole plant DCM/MeOH(1:1) 21.0 6.7 2.7 1.4 101.3 35.2 62.6 2.1 
Goodeniaceae Scaevola plumieri (L.) Vahl P08206b Twigs  DCM/MeOH (1:1) 6.5 10.0 0.0 0.7 26.8 5.4 22.2 0.0 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00245b Leaves DCM/MeOH (1:1) 22.6 7.8 0.0 0.0 68.7 16.4 64.1 16.4 
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Araliaceae Schefflera umbellifera (Sond.) Baill. P00245c Leaves MeOH 8.0 11.4 0.0 0.0 39.0 10.6 23.5 4.8 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00246a Roots DCM 0.0 10.7 0.0 0.0 80.1 16.0 25.7 9.4 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00246b Roots DCM/MeOH (1:1) 0.0 16.0 0.0 0.0 71.1 15.3 39.1 6.2 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00248a Stem bark DCM 4.5 0.0 8.5 0.0 57.0 9.2 45.7 4.6 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00248b Stem bark DCM/MeOH (1:1) 0.0 0.0 0.0 0.0 49.0 12.3 28.0 0.0 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00248c Stem bark MeOH 10.4 6.0 0.0 0.0 28.0 6.3 2.9 0.0 
Araliaceae Schefflera umbellifera (Sond.) Baill. P00248d Stem bark Aqueous 13.2 14.7 8.7 10.4 17.0 9.2 0.0 0.0 
Asteraceae Senecio oxyriifolius DC. P08209b Whole plant DCM/MeOH(1:1) 0.0 7.3 9.0 0.0 32.4 10.1 51.3 5.7 
Fabaceae Senna didymobotrya  P08219b Leaves DCM/MeOH (1:1) 13.2 0.4 0.0 2.9 30.8 1.2 35.5 2.6 
Fabaceae Senna didymobotrya  P08220b Twigs  DCM/MeOH (1:1) 21.6 17.1 0.0 0.0 39.4 5.0 54.0 9.5 
Fabaceae Senna didymobotrya  P08221b Pods DCM/MeOH (1:1) 9.6 1.8 0.0 0.0 29.1 7.7 34.5 3.3 
Fabaceae Senna didymobotrya  P08220c Twigs  Aqueous 11.0 7.7 10.8 1.9 30.1 14.7 0.0 0.0 
Fabaceae Senna didymobotrya  P08219c Leaves Aqueous 3.2 3.3 0.0 0.0 12.9 3.1 0.0 0.0 
Fabaceae Senna petersiana (Bolle) Lock P18564c Leaves Aqueous 1.5 0.0 3.5 3.8 28.0 23.2 0.0 1.1 
Fabaceae Senna petersiana (Bolle) Lock P18565c Twigs  Aqueous 0.0 1.7 14.8 7.5 30.6 20.8 0.0 0.0 
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Poaceae Setaria megaphylla  P12880b Whole plant DCM/MeOH (1:1) 18.1 2.0 3.8 7.4 34.1 4.0 99.8 19.0 
Asteraceae Spilanthes mauritiana (Pers.) DC. P00274a Stem bark DCM 10.9 10.0 0.0 0.0 60.0 8.5 70.6 0.8 
Asteraceae Spilanthes mauritiana (Pers.) DC. P00274b Stem bark DCM/MeOH (1:1) 2.0 11.3 0.1 0.0 35.4 9.0 29.8 1.3 
Asteraceae Spilanthes mauritiana (Pers.) DC. P00274c Stem bark MeOH 4.3 0.0 0.0 0.0 17.2 0.6 0.0 0.0 
Myrtaceae Syzigium cordatum  P18315c Twigs  Aqueous 13.1 16.4 2.5 8.2 15.3 6.1 16.9 0.0 
Myrtaceae Syzigium cordatum  P18315b Twigs  DCM/MeOH (1:1) 0.0 0.9 0.0 0.0 51.1 16.4 54.0 10.8 
Myrtaceae Syzigium cordatum  P18316b Leaves DCM/MeOH (1:1) 0.0 4.7 0.0 0.0 56.5 11.6 41.6 0.0 
Myrtaceae Syzigium cordatum  P18316c Leaves Aqueous 0.0 0.0 0.0 0.0 9.3 0.0 84.0 0.0 
Asteraceae Tarchonanthus camphoratus L. P01089a Leaves DCM 85.8 0.0 7.4 0.9 75.2 15.8 76.1 1.6 
Asteraceae Tarchonanthus camphoratus L. P01089b Leaves DCM/MeOH (1:1) 14.2 0.0 0.0 0.0 62.0 7.8 41.7 0.0 
Asteraceae Tarchonanthus camphoratus L. P01154b Roots DCM/MeOH (1:1) 95.4 0.0 0.0 0.0 52.3 1.4 17.5 3.9 
Asteraceae Tarchonanthus camphoratus L. P02554b Whole plant DCM/MeOH (1:1) 98.9 63.8 6.0 1.1 100.0 24.8 49.3 0.0 
Lamiaceae Tetradenia riparia (Hochst.) Codd P00741a Leaves DCM 0.0 0.0 0.0 2.4 36.4 0.0 37.8 0.0 
Lamiaceae Tetradenia riparia (Hochst.) Codd P00741b Leaves DCM/MeOH (1:1) 6.4 0.0 1.6 2.0 16.0 0.0 7.4 7.1 
Lamiaceae Tetradenia riparia (Hochst.) Codd P00741d Leaves Aqueous 0.0 6.8 4.2 6.7 9.5 0.0 0.0 0.0 
Meliaceace Trichilia emetica Vahl subsp. emetica P02470c Twigs/Leaves Aqueous 13.0 6.0 0.0 0.0 15.2 6.8 0.8 0.0 
Meliaceace Turraea floribunda Hochst. P15192c Leaves Aqueous 23.9 27.5 0.0 1.5 20.7 4.9 1.2 3.7 
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Rubiaceae Vangueria infausta P02497b Fruits DCM/MeOH (1:1) 2.7 4.2 0.0 0.0 33.2 0.0 32.6 0.0 
Asteraceae Vernonia colorata  P18569c Twigs  Aqueous 0.0 6.0 5.7 8.5 29.4 19.2 1.5 0.0 
Asteraceae Vernonia fastigiata Oliv. & Hiern P00393b Leaves DCM/MeOH (1:1) 58.3 3.7 0.0 0.0 28.7 0.0 30.3 0.0 
Asteraceae Vernonia fastigiata Oliv. & Hiern P00393c Leaves MeOH 10.0 10.9 0.0 0.0 23.9 8.1 21.1 0.0 
Asteraceae Vernonia hirsuta  P02834b Whole plant DCM/MeOH (1:1) 99.1 4.9 0.0 0.0 80.6 6.2 45.8 0.0 
Asteraceae Vernonia myriantha Hook.f. P00170a Roots DCM 0.0 0.0 0.0 0.0 19.0 0.0 20.9 0.0 
Asteraceae Vernonia myriantha Hook.f. P00170b Roots DCM/MeOH (1:1) 6.3 14.6 0.0 0.0 30.6 9.9 16.1 4.9 
Asteraceae Vernonia myriantha Hook.f. P00170d Roots Aqueous 7.2 7.7 0.0 0.0 17.2 6.1 16.1 7.5 
Asteraceae Vernonia myriantha Hook.f. P00171a Leaves DCM 4.7 10.1 0.0 0.0 33.8 10.1 35.1 1.4 
Asteraceae Vernonia myriantha Hook.f. P00171b Leaves DCM/MeOH (1:1) 6.4 9.9 0.0 0.0 22.7 9.4 11.3 0.0 
Asteraceae Vernonia myriantha Hook.f. P00170c Roots MeOH 9.7 0.0 0.0 0.0 22.3 3.6 0.0 0.0 
Asteraceae Vernonia natalensis P08212b Whole plant DCM/MeOH (1:1) 99.9 4.5 1.1 2.3 45.6 7.8 56.7 10.5 
Asteraceae Vernonia oligocephala  P00989b Roots DCM/MeOH (1:1) 0.0 0.0 2.7 0.0 13.5 1.4 24.2 0.0 
Asteraceae Vernonia oligocephala  P01015a Leaves DCM 99.0 78.0 23.1 0.0 59.5 3.7 88.7 11.0 
Asteraceae Vernonia oligocephala  P01015b Leaves DCM/MeOH (1:1) 99.3 0.0 0.0 0.0 20.9 6.3 29.4 0.0 
Olacaceae Ximenia caffra Sond. var. caffra P00351a Leaves DCM 0.0 6.8 0.0 0.0 30.6 6.4 11.7 0.0 
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Olacaceae Ximenia caffra Sond. var. caffra P00351b Leaves DCM/MeOH (1:1) 0.0 6.6 0.0 0.0 16.0 10.2 6.0 0.0 
Olacaceae Ximenia caffra Sond. var. caffra P00351d Leaves Aqueous 8.2 10.5 4.6 4.3 17.2 0.0 0.0 0.0 
Olacaceae Ximenia caffra Sond. var. caffra P00352a Roots DCM 4.5 12.3 0.0 0.0 21.4 4.0 1.3 0.0 
Olacaceae Ximenia caffra Sond. var. caffra P00352b Roots DCM/MeOH (1:1) 1.3 2.4 0.0 0.0 15.8 8.1 0.0 0.0 
Olacaceae Ximenia caffra Sond. var. caffra P00352c Roots MeOH 1.4 6.9 0.0 0.0 18.8 3.6 0.0 0.0 
Apocynaceae Xysmalobium undulatum (L.) Aiton.f. P12869b Whole plant DCM/MeOH(1:1) 8.3 9.7 0.0 0.0 29.6 0.0 28.2 0.5 
Cucurbitaceae Zehneria scabra  P08210b Whole plant DCM/MeOH (1:1) 4.7 8.3 9.3 5.9 21.5 0.0 20.8 5.4 
Cucurbitaceae Zehneria scabra  P08210c whole plant Aqueous 27.6 0.0 0.0 3.8 17.4 12.7 0.0 4.2 
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Table 2.2 Antiprotozoal in vitro activity (IC50 values in µg/mL) of 43 plant extracts against Trypanosoma brucei rhodesiense, Trypanosoma 
cruzi, Leishmania donovani and Plasmodium falciparum. Extracts were considered “potential hits” when they inhibited one or more of the 
parasites at 9.7 µg/mL in a preliminary first screen (Appendix 1, Table 2.1). The positive controls melarsoprol, benznidazol, miltefosine, 
chloroquine and podophyllotoxin were tested likewise. Tests were done twice in duplicate. 
 
Plant name Plant part Bioprospecting no. Extract Type T. b. rhodesiense T. cruzi L. donovani P. falciparum Cytotoxicity 
Agathosma apiculata  Whole plant P09995b DCM/MeOH (1:1) 11.10 41.50 16.00 0.21 42.90 
Agathosma puberula. Roots P02011a DCM 32.20 28.90 15.10 8.53 57.90 
Alepidea amatymbica  Whole plant P02873b DCM/MeOH (1:1) 20.30 73.10 12.10 3.70 52.70 
Artabotrys monteiroae  Leaves P18314b DCM/MeOH (1:1) 10.30 41.30 16.60 8.79 40.90 
Artemisia afra  Leaves P00484b DCM/MeOH (1:1) 21.90 54.50 8.80 7.50 15.80 
Artemisia afra Leaves P00484a DCM 9.60 27.60 5.68 6.22 21.50 
Artemisia afra  Leaves P00484c MeOH 15.90 41.80 15.10 13.30 47.40 
Asystasia gangetica  Leaves P05623b DCM/MeOH (1:1) 13.20 74.70 12.40 4.20 15.90 
Catha edulis Roots P00469a DCM 14.20 19.10 7.65 4.91 17.80 
Conyza albida Spreng. Whole plant P12954b DCM/MeOH (1:1) 18.80 38.30 16.20 5.79 40.80 
Conyza podocephala  Whole plant P03063b DCM/MeOH (1:1) 13.90 47.20 15.80 5.45 51.60 
Conyza scabrida Leaves P03170b DCM/MeOH (1:1) 30.00 49.40 6.65 6.66 48.10 
Croton menyhartii Leaves P12951b DCM/MeOH (1:1) 11.70 33.30 15.80 2.63 46.40 
Croton menyhartii Twigs P12952b DCM/MeOH (1:1) 11.30 41.10 15.90 2.88 45.40 
Croton menyhartii Whole plant P14867b DCM/MeOH (1:1) 8.76 38.60 16.30 10.80 51.10 
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Cymbopogon validus Whole plant P12881b DCM/MeOH (1:1) 11.90 47.10 17.90 6.67 48.70 
Ekebergia capensis Fruits P03111b DCM/MeOH (1:1) 11.50 24.40 4.80 3.50 9.90 
Ekebergia capensis  Twigs P03112b DCM/MeOH (1:1) 15.60 46.40 15.90 13.30 55.40 
Euclea natalensis  Roots P08227b DCM/MeOH (1:1) 28.10 43.70 14.80 7.59 57.90 
Eucomis autumnalis Flowers/Buds P01463a DCM 37.10 29.70 7.62 22.10 51.30 
Helichrysum nudifolium Whole plant P02847b DCM/MeOH (1:1) 33.10 43.90 15.30 9.36 47.70 
Hypericum aethiopicum Leaves P02817b DCM/MeOH (1:1) 4.47 18.10 4.74 2.35 15.20 
Leonotis leonurus Leaves P03269b DCM/MeOH (1:1) 14.70 50.10 4.70 2.90 14.10 
Leonotis ocymifolia  Leaves P00480a DCM 9.10 63.50 18.50 2.70 22.10 
Leonotis ocymifolia  Leaves P00480b DCM/MeOH (1:1) 9.70 91.20 13.30 4.50 18.20 
Maytenus undata  Roots P00153a DCM 35.20 28.40 5.58 8.53 52.40 
Pentzia globosa Roots P01516a DCM 5.76 31.30 14.40 4.27 50.20 
Pentzia globosa Stem bark P01517a DCM 6.32 46.50 22.00 6.04 63.90 
Pentzia globosa Roots P01516b DCM/MeOH (1:1) 6.69 40.60 17.50 6.89 54.20 
Pentzia globosa Stem bark P01517b DCM/MeOH (1:1) 15.20 55.60 49.50 9.14 >100.00 
Plumbago zeylanica Leaves P00631b DCM/MeOH (1:1) 13.00 54.50 17.80 12.40 14.40 
Ptaeroxylon obliquum  Leaves P01870a DCM 11.30 41.50 17.20 10.90 46.30 
Rauvolfia caffra Roots P00734a DCM 17.90 41.10 15.50 8.44 46.60 
Salvia repens Whole plant P08214b DCM/MeOH (1:1) 10.80 36.20 5.36 7.65 41.50 
Schefflera umbellifera Roots P00246a DCM 20.90 57.60 5.03 2.70 13.90 
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Schefflera umbellifera Roots P00246b DCM/MeOH (1:1) 30.20 99.50 14.10 7.70 48.30 
Setaria megaphylla Whole plant P12880b DCM/MeOH (1:1) 16.80 43.90 16.90 4.44 48.10 
Tarchonanthus camphoratus Roots P01154b DCM/MeOH (1:1) 13.40 42.90 16.30 17.70 31.90 
Tarchonanthus camphoratus Whole plant P02554b DCM/MeOH (1:1) 3.93 18.60 4.86 6.23 16.10 
Vernonia hirsuta Whole plant P02834b DCM/MeOH (1:1) 18.10 43.00 16.20 10.20 31.60 
Vernonia natalensis Whole plant P08212b DCM/MeOH (1:1) 12.60 39.30 17.20 8.53 38.60 
Vernonia oligocephala  Leaves P01015a DCM 4.67 14.30 16.10 7.69 6.54 
Vernonia oligocephala  Leaves P01015b DCM/MeOH (1:1) 10.90 44.50 19.90 9.51 22.30 
Melarsoprol    0.004     
Benznidazole     0.48    
Miltefosine      0.24   
Chloroquine       0.052  
Podophyllotoxin        0.003 
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Table 4.1 Antiprotozoal activity of 60 South African Medicinal plants species against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, 
Leishmania donovani and P. falciparum. The activity was expressed as percentage (%) growth inhibition. Plants extracts showing more than 
95% growth inhibition at 10 µg/ml were considered potential “hits”. The tests were done twice and in duplicate. 
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Fabaceae Abrus precatorius africanus Whole plant DCM/MeOH (1:1) P06218B 100.0 100.0 44.0 16.7 75.5 16.1 97.8 37.0 
Fabaceae Acacia caffra Leaves DCM/MeOH (1:1) P00855B 3.0 0.0 42.3 17.6 33.5 8.3 19.9 0.3 
Fabaceae Acacia caffra Roots DCM/MeOH (1:1) P00866B 93.9 0.0 46.1 25.7 34.7 8.9 55.0 7.0 
Fabaceae Acacia erioloba Roots DCM/MeOH (1:1) P08470B 18.6 6.4 48.9 18.8 50.2 26.3 61.4 72.6 
Euphorbiaceae Acalypha peduncularis. leaves DCM/MeOH (1:1) P02855B 98.8 0.0 37.2 8.5 60.2 0.0 77.7 19.2 
Asparagaceae Asparagus virgatus Leaves DCM/MeOH (1:1) P00558B 10.3 0.0 47.6 15.7 0.0 0.0 36.5 0.0 
Lamiaceae Becium obovatum  Roots DCM/MeOH (1:1) P04123B 49.4 11.9 37.5 3.9 97.5 5.7 99.3 38.2 
Scrophulariaceae Bowkeria cymosa leaves DCM/MeOH (1:1) P11785B 46.1 17.6 59.8 26.2 94.1 31.2 87.0 27.8 
Scrophulariaceae Bowkeria cymosa Twigs DCM/MeOH (1:1) P11786B 14.0 4.6 36.9 8.4 47.5 24.3 60.1 7.6 
Scrophulariaceae Bowkeria cymosa Roots DCM/MeOH (1:1) P11787B 17.1 0.0 53.0 15.2 39.9 17.0 80.7 14.6 
Scrophulariaceae Bowkeria cymosa stems DCM/MeOH (1:1) P11788B 5.6 0.0 54.0 22.3 31.7 17.1 45.2 3.5 
Asteraceae Brachylaena discolor Roots DCM/MeOH (1:1) P04199B 20.9 10.3 35.0 7.4 28.9 14.5 38.2 4.8 
Asteraceae Brachylaena discolor leaves DCM/MeOH (1:1) P04321B 50.0 12.6 34.2 15.3 30.4 19.0 71.5 10.3 
Asteraceae Brachylaena discolor Roots DCM/MeOH (1:1) P04459B 37.0 16.0 37.4 15.4 36.4 18.8 60.2 15.9 
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Euphorbiaceae Bridelia micrantha leaves DCM/MeOH (1:1) P04722B 98.0 0.0 38.2 11.6 30.7 0.0 84.3 12.8 
Euphorbiaceae Bridelia micrantha Stems DCM/MeOH (1:1) P04806B 58.4 24.3 37.5 13.7 54.0 20.0 92.5 23.3 
Euphorbiaceae Bridelia micrantha Roots DCM/MeOH (1:1) P04815B 42.0 0.0 30.6 14.3 15.8 0.0 80.7 34.6 
Rubiaceae Canthium mundianum Leaves DCM/MeOH (1:1) P00413B 12.8 0.0 48.9 20.2 30.7 23.0 24.1 0.0 
Rubiaceae Canthium mundianum Leaves MeOH P00413C 10.1 0.0 45.0 16.3 30.8 28.3 22.6 0.0 
Rubiaceae Canthium mundianum Roots DCM P00414A 23.1 0.0 49.9 22.3 65.7 22.4 87.1 15.5 
Rubiaceae Canthium mundianum Roots DCM/MeOH (1:1) P00414B 14.5 0.0 49.9 18.5 31.8 21.4 29.6 0.0 
Rubiaceae Canthium mundianum Roots MeOH P00414C 12.8 0.0 43.0 24.7 29.4 19.8 30.1 0.0 
Rubiaceae Canthium mundianum Fruits DCM/MeOH (1:1) P00415B 10.6 0.0 46.7 20.3 20.5 19.0 26.3 0.0 
Rubiaceae Canthium mundianum Fruits MeOH P00415C 0.7 0.0 38.1 9.7 0.0 0.0 25.2 0.1 
Capparaceae 
 
Capparis tomentosa Lam. 
 
Roots DCM/MeOH (1:1) P06167B 31.2 30.2 30.5 13.1 35.1 23.8 76.3 26.4 
Fruits DCM/MeOH (1:1) P06168B 17.7 0.0 24.8 15.7 17.6 19.6 37.8 3.7 





Whole plant DCM P02112A 10.2 0.0 49.1 30.2 33.1 24.9 46.3 0.0 
Whole plant DCM/MeOH (1:1) P02112B 23.2 5.3 42.9 29.3 30.7 27.6 49.1 0.0 
Leaves DCM/MeOH (1:1) P06377B 11.3 1.4 42.2 10.2 39.7 18.4 81.0 20.6 
Roots DCM/MeOH (1:1) P06381B 28.7 1.8 8.3 5.3 38.2 16.7 51.9 11.8 
Asteraceae Cirsium vulgare Stems DCM/MeOH (1:1) P06384B 5.9 0.0 46.8 20.6 35.3 15.2 70.6 16.5 
rutaceae Clausena anisata  leaves DCM/MeOH (1:1) P04413B 98.8 13.6 28.8 8.7 53.3 4.5 77.8 15.4 
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rutaceae Clausena anisata  Roots DCM/MeOH (1:1) P04411B 82.5 6.3 25.0 7.1 71.4 1.4 100.0 51.5 
Verbebaceae Clerodendrumglabrumglabrum Stems DCM/MeOH (1:1) P09466B 5.5 0.0 42.3 15.3 42.8 18.7 82.5 19.1 
Verbebaceae Clerodendrumglabrumglabrum Roots DCM/MeOH (1:1) P09467B 19.7 0.0 50.0 17.7 69.8 31.5 58.6 4.5 
Euphorbiaceae Clutiapulchellapulchella Twigs DCM P00020A 18.2 6.8 28.8 16.7 38.2 21.3 69.4 2.4 
Euphorbiaceae Clutiapulchellapulchella Twigs DCM/MeOH (1:1) P00020B 20.0 10.8 37.6 23.1 33.3 20.9 38.0 2.7 
Euphorbiaceae Clutiapulchellapulchella Twigs MeOH P00020C 18.3 9.9 38.1 16.5 31.9 19.3 36.0 0.0 
Euphorbiaceae Clutiapulchellapulchella Leaves DCM/MeOH (1:1) P00476B 11.8 4.7 48.2 24.6 34.3 24.9 59.9 1.1 
Euphorbiaceae Clutiapulchellapulchella Leaves MeOH P00476C 3.8 0.0 48.5 22.6 31.2 20.6 53.1 8.3 
Euphorbiaceae Clutiapulchellapulchella Roots DCM/MeOH (1:1) P10738B 12.5 1.9 47.6 16.6 14.2 0.0 97.7 75.0 
Euphorbiaceae Clutiapulchellapulchella Leaves & stems DCM/MeOH (1:1) P10739B 42.3 8.3 34.7 19.9 40.1 14.1 74.0 12.5 
Euphorbiaceae Clutiapulchellapulchella Stems DCM/MeOH (1:1) P10740B 19.2 5.0 40.2 24.3 48.3 17.1 76.8 19.1 
Euphorbiaceae Croton gratissimus  Leaves DCM/MeOH (1:1) P07086B 40.1 3.2 38.0 15.6 96.4 26.1 71.8 27.1 
Euphorbiaceae Croton gratissimus  Stems DCM/MeOH (1:1) P07087B 38.9 6.4 25.3 12.7 60.6 0.0 83.2 42.9 
Euphorbiaceae Croton gratissimus  Bark DCM/MeOH (1:1) P07089B 100.0 1.9 13.3 16.0 67.2 29.6 79.6 31.0 
Iridaceae Dietes iridioides Leaves DCM/MeOH (1:1) P08597B 98.8 0.0 43.5 22.9 30.4 18.1 69.4 8.4 
Iridaceae Dietes iridioides Roots DCM/MeOH (1:1) P08598B 97.9 0.0 35.0 0.0 0.0 0.0 77.7 24.0 
Iridaceae Dietes iridioides Flowers DCM/MeOH (1:1) P08599B 99.9 0.0 41.8 13.1 55.8 17.1 69.9 24.8 
Iridaceae Dietes iridioides Fruits DCM/MeOH (1:1) P08600B 100.0 4.7 31.3 12.2 42.8 19.3 76.9 12.1 
Apocynaceae Diplorhynchus condylocarpon Leaves DCM P00933A 20.6 0.0 49.0 26.5 80.4 28.2 78.2 9.9 
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Apocynaceae Diplorhynchus condylocarpon Leaves DCM/MeOH (1:1) P00933B 6.0 0.0 46.0 16.1 35.5 25.2 37.9 0.0 
Apocynaceae Diplorhynchus condylocarpon Roots DCM P00940A 12.7 0.0 38.9 18.2 57.3 27.2 43.8 0.0 
Apocynaceae Diplorhynchus condylocarpon Roots DCM/MeOH (1:1) P00940B 18.6 0.0 58.7 13.9 35.3 26.5 61.7 0.0 
Apocynaceae Diplorhynchus condylocarpon Twigs DCM/MeOH (1:1) P03406B 14.7 0.0 50.0 17.8 54.6 15.7 73.0 10.0 
Apocynaceae Diplorhynchus condylocarpon Leaves & Twigs DCM/MeOH (1:1) P03407B 40.0 3.0 34.5 5.3 86.2 18.9 97.4 19.5 
Apocynaceae Diplorhynchus condylocarpon Stems DCM/MeOH (1:1) P07108B 21.1 1.9 40.2 10.3 47.1 24.9 93.3 28.2 
Euphorbiaceae Drypetes gerrardii  Stems DCM/MeOH (1:1) P05778B 60.7 28.5 30.9 0.0 80.5 24.9 100.0 99.5 
Euphorbiaceae Drypetes gerrardii  Leaves DCM/MeOH (1:1) P05800B 96.5 37.3 32.0 6.9 28.1 23.6 69.9 21.6 
Meliaceae Ekebergia capensis Leaves DCM/MeOH (1:1) P04616B 98.8 0.9 39.3 13.3 50.6 0.0 71.9 13.8 
Meliaceae Ekebergia capensis Roots DCM/MeOH (1:1) P04929B 100.0 100.0 102.4 95.3 100.0 56.9 98.6 57.0 
Euphorbiaceae Euphorbia clavarioides  Leaves DCM/MeOH (1:1) P01559B 7.6 0.0 37.8 32.4 42.5 12.5 59.9 12.7 
Euphorbiaceae Euphorbia clavarioides Roots DCM/MeOH (1:1) P01568B 17.2 0.0 46.8 25.5 45.9 17.4 63.9 5.4 
Euphorbiaceae Euphorbia pulcherrima Leaves DCM/MeOH (1:1) P10453B 11.8 0.0 30.7 21.1 42.8 20.4 63.4 6.3 
Euphorbiaceae Euphorbia pulcherrima Stems DCM/MeOH (1:1) P10454B 17.8 0.0 45.6 15.4 55.2 22.9 86.5 16.4 
Euphorbiaceae Euphorbia pulcherrima Roots DCM/MeOH (1:1) P10455B 13.5 0.0 45.4 17.4 42.7 18.5 81.7 23.2 
Asteraceae Felicia filifolia Leaves DCM/MeOH (1:1) P10676B 7.3 1.1 45.2 11.5 0.0 14.9 88.2 19.3 
Asteraceae Helichrysum mundtii Stems DCM P00464A 19.3 0.0 79.0 34.9 64.7 31.0 84.3 20.7 
Asteraceae Helichrysum mundtii Stems DCM/MeOH (1:1) P00464B 9.9 4.4 75.4 33.2 61.5 28.0 81.1 14.2 
Asteraceae Helichrysum mundtii Stems MeOH P00464C 2.0 0.0 59.2 26.7 38.4 29.5 34.9 0.0 
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Asteraceae Helichrysum mundtii Roots DCM P00466A 38.8 0.0 89.9 44.2 80.7 35.1 89.7 19.9 
Asteraceae Helichrysum mundtii Roots DCM/MeOH (1:1) P00466B 15.2 0.7 73.7 32.8 47.8 27.4 71.5 3.2 
Asteraceae Helichrysum mundtii Roots MeOH P00466C 17.3 0.0 58.9 28.0 36.9 23.9 55.2 0.0 
Asteraceae Helichrysum mundtii Leaves DCM/MeOH (1:1) P00467B 7.7 0.0 52.2 19.0 32.3 21.2 46.5 0.3 
Asteraceae Helichrysum mundtii Leaves MeOH P00467C 5.5 0.0 46.1 15.2 0.0 0.0 37.1 3.5 
Asteraceae Helichrysum pedunculatum  Whole plants DCM/MeOH (1:1) P08309B 9.2 0.0 40.0 8.1 36.3 31.8 61.9 24.0 
Apiaceae Heteromorpha arborescens  Roots DCM/MeOH (1:1) P12488B 17.3 0.0 40.2 26.8 38.0 32.0 66.2 27.7 
Apiaceae Heteromorpha arborescens  Bark DCM/MeOH (1:1) P12489B 19.0 0.0 33.4 14.9 44.8 28.2 84.0 26.5 
Lamiaceae Hyptis pectinata (L.) Poit. 
Leaves,stems,fru
it 
DCM/MeOH (1:1) P02459B 32.2 0.0 53.4 17.4 53.5 18.2 85.0 19.9 
Proteaceae Leucospermum cuneiforme  Leaves DCM/MeOH (1:1) P02599B 21.8 6.4 44.0 23.1 50.6 10.5 99.4 21.3 
Proteaceae Leucospermum cuneiforme  Roots DCM/MeOH (1:1) P02606B 18.5 3.3 49.0 19.7 11.1 3.5 41.2 9.9 
Euphorbiaceae Macaranga capensis Leaves DCM/MeOH (1:1) P04676B 83.4 7.9 55.0 17.2 49.6 0.0 91.7 22.0 
Sapotaceae Mimusops zeyheri Sond. Leaves DCM P00488A 18.1 0.0 49.2 25.9 42.5 22.9 71.1 3.4 
Sapotaceae Mimusops zeyheri Sond. Leaves MeOH P00488C 99.3 0.0 50.8 24.2 28.5 23.3 30.1 0.0 
Sapotaceae Mimusops zeyheri Sond. Fruits DCM P00489A 18.6 0.0 48.0 27.0 40.6 26.8 53.2 0.0 
Sapotaceae Mimusops zeyheri Sond. Fruits MeOH P00489C 6.7 0.0 45.2 27.9 48.5 26.2 26.2 0.0 
Sapotaceae Mimusops zeyheri Sond. Roots DCM P00490A 10.3 0.0 46.7 22.1 45.9 27.9 83.4 9.3 
Sapotaceae Mimusops zeyheri Sond. Roots MeOH P00490C 9.4 0.0 41.6 23.3 35.0 22.9 27.3 0.0 
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Sapotaceae Mimusops zeyheri Sond. Stems DCM P00491A 12.8 0.0 40.9 29.0 56.0 27.2 88.7 14.8 
Sapotaceae Mimusops zeyheri Sond. Stems MeOH P00491C 17.6 0.0 48.1 27.8 27.7 21.9 23.8 0.0 
Sapotaceae Mimusops zeyheri Sond. Leaves & twigs DCM P02237A 34.0 0.0 48.0 25.3 61.6 27.9 98.5 16.6 
Sapotaceae Mimusops zeyheri Sond. Leaves & twigs DCM/MeOH (1:1) P02237B 99.5 0.0 42.5 24.9 27.4 23.0 26.4 0.0 
Euphorbiaceae Monadenium lugardiae Whole plants DCM/MeOH (1:1) P02587B 97.8 2.3 40.6 15.8 69.5 16.1 97.7 27.7 
Lamiaceae Ocimum gratissimum Leaves DCM P00766A 12.3 0.0 47.9 29.2 55.5 14.6 88.7 25.7 
Lamiaceae Ocimum gratissimum  Leaves DCM/MeOH (1:1) P00766B 0.3 0.0 43.2 21.3 0.0 0.0 51.9 21.0 
Lamiaceae Ocimum gratissimum  Roots DCM/MeOH (1:1) P00775B 6.7 4.8 45.6 11.8 30.5 11.6 22.0 10.8 
Lamiaceae Ocimum gratissimum  Stems DCM P00777A 26.5 3.7 39.0 22.9 52.9 17.9 90.5 29.2 
Lamiaceae Ocimum gratissimum Stems DCM/MeOH (1:1) P00777B 0.5 0.0 44.3 22.0 33.6 11.5 28.4 0.0 
Asteraceae Oedera genistifolia (L.)  Whole plant DCM/MeOH (1:1) P03206B 100.0 100.0 50.8 18.6 100.0 69.8 100.0 99.3 
Asteraceae Othonna carnosa  Stems DCM/MeOH (1:1) P02700B 100.0 2.3 43.9 17.1 29.0 3.8 98.5 37.8 
Anacardiaceae Ozoroa sphaerocarpa  Whole plant DCM P00437A 100.0 67.1 41.9 23.2 87.1 22.8 74.7 15.7 
Anacardiaceae Ozoroa sphaerocarpa  Whole plant DCM/MeOH (1:1) P00437B 100.0 0.0 51.1 24.0 82.7 26.1 81.5 18.1 
Anacardiaceae Ozoroa sphaerocarpa  Whole plant MeOH P00437C 99.6 0.0 40.2 10.9 33.3 24.1 39.1 0.0 
Anacardiaceae Ozoroa sphaerocarpa  Stems DCM P00439A 3.6 0.0 42.7 15.8 97.4 23.7 85.9 25.1 
Anacardiaceae Ozoroa sphaerocarpa  Stems DCM/MeOH (1:1) P00439B 99.1 0.0 40.3 29.5 39.9 23.3 54.9 0.0 
Anacardiaceae Ozoroa sphaerocarpa  Stems MeOH P00439C 99.6 0.0 35.1 21.9 30.1 25.3 31.2 1.4 
Anacardiaceae Ozoroa sphaerocarpa  Leaves DCM/MeOH (1:1) P00440B 100.0 0.0 34.2 24.3 43.7 22.6 47.7 0.0 
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Anacardiaceae Ozoroa sphaerocarpa  Leaves DCM P00440A 98.3 0.0 42.2 20.4 80.2 25.2 82.0 13.4 
Anacardiaceae Ozoroa sphaerocarpa  Leaves MeOH P00440C 100.0 0.0 42.3 26.7 32.0 20.8 22.8 0.0 
Sapindaceae Pappea capensis Roots DCM P00397A 100.0 9.7 34.0 17.6 40.5 14.8 76.0 100.0 
Sapindaceae Pappea capensis Roots DCM/MeOH (1:1) P00397B 0.1 0.0 40.0 14.7 0.0 0.0 37.4 4.5 
Sapindaceae Pappea capensis Roots MeOH P00397C 19.5 0.0 46.0 26.6 30.7 25.3 36.7 1.1 
Sapindaceae Pappea capensis Leaves DCM/MeOH (1:1) P10670B 99.7 0.0 17.6 15.5 15.5 0.0 79.2 35.9 
Sapindaceae Pappea capensis Bark DCM/MeOH (1:1) P10671B 14.5 0.0 29.7 22.4 30.6 22.2 78.3 25.8 
Sapindaceae Pappea capensis Roots DCM/MeOH (1:1) P10673B 15.2 0.0 29.5 25.7 44.5 25.4 95.9 54.1 
Geraniaceae Pelargonium zonale  Stems DCM P01688A 1.7 0.0 43.4 5.1 26.0 23.6 30.9 0.0 
Geraniaceae Pelargonium zonale  Stems DCM/MeOH (1:1) P01688B 99.4 0.0 40.0 21.8 28.7 24.1 33.5 0.0 
Geraniaceae Pelargonium zonale  Twigs DCM/MeOH (1:1) P03391B 15.7 4.1 44.4 19.9 26.9 17.2 52.1 5.1 
Geraniaceae Pelargonium  Leaves DCM/MeOH (1:1) P03392B 16.4 2.8 43.4 11.2 24.0 10.1 88.2 3.9 
Fabaceae Peltophorum africanum Roots DCM P00394A 99.9 26.0 34.2 18.6 44.9 21.0 84.3 17.4 
Fabaceae Peltophorum africanum Roots DCM/MeOH (1:1) P00394B 100.0 8.2 34.9 18.0 26.2 20.6 54.0 2.0 
Fabaceae Peltophorum africanum Roots MeOH P00394C 100.0 6.1 32.1 12.2 23.9 21.7 34.8 0.0 
Fabaceae Peltophorum africanum Stems DCM P00401A 99.6 49.3 60.7 29.0 31.5 22.4 90.2 31.6 
Fabaceae Peltophorum africanum Stems DCM/MeOH (1:1) P00401B 100.0 10.6 52.4 25.2 28.8 21.6 63.8 11.4 
Fabaceae Peltophorum africanum Stems MeOH P00401C 100.0 11.6 51.6 15.2 29.8 22.0 66.5 9.2 
Fabaceae Peltophorum africanum Leaves & twigs DCM P02244A 100.0 0.0 56.5 23.9 78.3 28.5 98.8 29.6 
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Fabaceae Peltophorum africanum Leaves & twigs DCM/MeOH (1:1) P02244B 57.6 0.0 40.6 22.1 28.2 22.8 49.7 3.7 
Fabaceae Peltophorum africanum leaves & twigs MeOH P02244C 95.4 0.0 40.5 6.7 0.0 0.0 30.3 0.0 
Asteraceae Phymaspermum acerosum Whole plant DCM/MeOH (1:1) P03661B 100.0 13.1 44.5 13.1 67.7 17.8 98.6 37.8 
Lamiaceae Plectranthus laxiflorus. Whole plants DCM/MeOH (1:1) P12870B 92.1 9.9 40.0 14.4 51.5 29.0 59.9 14.6 
Polygalaceae Polygala fruticosa  Leaves DCM/MeOH (1:1) P03756B 37.3 14.4 68.9 34.7 65.6 0.0 98.6 35.6 
Polygalaceae Polygala fruticosa  Twigs DCM/MeOH (1:1) P03757B 24.7 11.7 46.8 17.8 35.3 0.0 82.5 23.2 
Fabaceae Psoralea pinnata  Leaves DCM P01617A 98.7 100.0 36.6 30.0 91.9 26.9 98.8 19.0 
Fabaceae Psoralea pinnata  Leaves DCM/MeOH (1:1) P01617B 99.7 99.2 32.1 19.8 73.3 22.7 83.9 0.6 
Fabaceae Psoralea pinnata  Stems DCM P01676A 7.5 0.0 52.8 20.5 32.4 15.9 52.4 1.9 
Fabaceae Psoralea pinnata  Stems DCM/MeOH (1:1) P01676B 4.3 0.0 47.3 16.4 0.0 0.0 38.5 7.1 
Fabaceae Psoralea pinnata  Roots DCM P01679A 8.6 0.0 44.7 24.1 35.5 23.2 41.0 0.0 
Fabaceae Psoralea pinnata  Roots MeOH P01679C/B 8.2 0.0 44.9 12.4 24.5 21.2 39.3 0.0 
Rubiaceae Psychotria capensis  Roots DCM/MeOH (1:1) P09181B 17.4 0.0 31.1 13.0 39.0 21.4 28.9 5.5 
Rubiaceae Psychotria capensis  Leaves DCM/MeOH (1:1) P09182B 18.4 0.0 30.6 14.8 37.4 20.4 36.7 10.3 
Rubiaceae Psychotria capensis  Stems DCM/MeOH (1:1) P09183B 99.9 0.0 36.7 3.1 39.4 19.1 30.1 0.0 
Lamiaceae Rabdosiella calycina  Stems DCM P00451A 98.4 0.0 45.3 8.6 103.4 40.6 77.5 11.3 
Lamiaceae Rabdosiella calycina  Stems DCM/MeOH (1:1) P00451B 38.1 0.0 48.8 23.2 14.1 0.0 49.2 2.8 
Lamiaceae Rabdosiella calycina  Stems MeOH P00451C 99.9 0.0 44.4 18.3 59.7 24.6 51.2 9.6 
Lamiaceae Rabdosiella calycina  Leaves DCM/MeOH (1:1) P00453B 5.4 0.0 52.0 16.0 33.3 21.1 33.0 0.0 
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Lamiaceae Rabdosiella calycina  Leaves MeOH P00453C 0.0 0.0 44.4 26.5 32.5 21.9 27.9 0.0 
Lamiaceae Rabdosiella calycina  Whole plant DCM/MeOH (1:1) P08318B 99.6 0.0 44.1 12.1 80.4 22.6 76.9 20.6 
Myrsinaceae Rapanea melanophloeos  Leaves DCM/MeOH (1:1) P08222B 19.9 34.7 37.3 14.8 60.6 30.8 44.7 5.1 
Myrsinaceae Rapanea melanophloeos  Twigs DCM/MeOH (1:1) P08223B 95.8 0.0 41.3 15.5 100.0 28.5 43.1 10.8 
Myrsinaceae Rapanea melanophloeos  Stems DCM/MeOH (1:1) P09405B 33.3 0.0 32.1 8.7 38.7 17.8 16.6 0.6 
Myrsinaceae Rapanea melanophloeos  Roots DCM/MeOH (1:1) P09406B 99.0 0.0 38.3 18.6 67.0 20.6 17.8 13.0 
Vitaceae Rhoicissus tridentata Leaves DCM/MeOH (1:1) P09322B 82.2 0.0 46.0 16.8 39.5 18.5 37.0 4.1 
Vitaceae Rhoicissus tridentata Fruits DCM/MeOH (1:1) P09323B 99.7 0.0 41.1 17.6 47.0 25.7 54.3 11.7 
Vitaceae Rhoicissus tridentata  Roots DCM/MeOH (1:1) P09324B 0.0 0.0 46.7 24.6 38.5 20.8 30.4 9.9 
Vitaceae Rhoicissus tridentata  Bark DCM/MeOH (1:1) P09325B 97.9 0.0 44.4 19.8 29.9 17.7 32.1 1.0 
Vitaceae Rhoicissus tridentata  Stems DCM/MeOH (1:1) P09326B 13.5 0.0 45.2 22.1 26.5 14.8 50.9 2.3 
Apocynaceae Sarcostemma viminale Leaves MeOH P00363C 18.1 2.2 33.4 15.3 36.4 20.4 49.6 7.4 
Apocynaceae Sarcostemma viminale Stems DCM P01381A 12.1 0.0 40.1 27.4 38.4 23.8 70.0 2.7 
Apocynaceae Sarcostemma viminale Whole plant DCM/MeOH (1:1) P02503B 33.8 7.1 46.4 21.7 18.3 4.3 74.9 12.9 
Apocynaceae Sarcostemma viminale Roots DCM/MeOH (1:1) P06980B 99.5 7.0 46.3 20.0 57.6 24.3 99.3 31.8 
Asclepiadaceae Sarcostemma viminale Stems DCM/MeOH (1:1) P01381B 6.5 0.0 46.0 17.3 29.7 22.2 35.5 0.0 
Asteraceae Schkuhria pinnata  whole plants DCM/MeOH (1:1) P03491B 99.4 97.1 67.4 16.9 69.7 0.0 100.0 73.8 
Fabaceae Senna septemtrionalis  Roots DCM/MeOH (1:1) P06145B 43.0 5.9 33.8 17.2 24.9 22.0 45.6 14.4 
Fabaceae Senna septemtrionalis  Stems DCM/MeOH (1:1) P06146B 98.5 11.4 37.5 10.7 23.8 15.0 45.4 15.3 
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Fabaceae Senna septemtrionalis  Leaves DCM/MeOH (1:1) P06147B 39.7 9.7 40.2 18.7 33.9 13.4 83.7 18.5 
Fabaceae Senna septemtrionalis  Seeds DCM/MeOH (1:1) P06148B 0.0 0.0 34.7 12.7 0.5 0.0 33.6 11.4 
Apiaceae Steganotaenia araliacea Roots DCM P00758A 20.6 0.0 52.5 44.4 35.1 24.3 64.9 11.0 
Malvaceae Sterculia rogersii. Leaves DCM/MeOH (1:1) P03870B 100.0 13.0 32.8 8.6 44.7 18.4 61.6 18.6 
Malvaceae Sterculia rogersii  Roots DCM/MeOH (1:1) P03872B 14.1 5.9 35.8 13.8 39.9 14.7 42.4 15.6 
Malvaceae Sterculia rogersii  Bark DCM/MeOH (1:1) P03873B 32.9 33.7 25.1 12.5 62.0 18.4 91.9 30.2 
Rutaceae Toddalia asiatica Roots DCM/MeOH (1:1) P00599B 98.1 0.0 45.4 17.4 36.0 20.8 94.2 25.6 
Rutaceae Toddalia asiatica Leaves & twigs DCM/MeOH (1:1) P02460B 16.7 0.0 40.3 14.2 53.5 20.2 68.5 14.3 
Ulmaceae Trema orientalis Leaves DCM/MeOH (1:1) P11527B 98.3 0.0 82.3 10.9 100.0 27.6 94.5 24.3 
Ulmaceae Trema orientalis (L.) Blume Flowers DCM/MeOH (1:1) P11528B 3.6 0.0 36.2 14.3 41.7 23.0 85.0 21.2 
Ulmaceae Trema orientalis (L.) Blume Roots DCM/MeOH (1:1) P11529B 14.4 2.2 49.7 27.3 34.0 17.1 74.5 13.2 
Ulmaceae Trema orientalis (L.) Blume Stems DCM/MeOH (1:1) P11530B 11.7 3.1 46.9 18.3 0.0 19.2 88.8 27.1 
Meliaceae Turraea floribunda Hochst. Bark DCM/MeOH (1:1) P05214B 93.5 12.8 28.3 15.6 28.4 20.4 89.9 39.9 
Meliaceae Turraea floribunda Hochst. leaves DCM/MeOH (1:1) P05294B 100.0 14.2 38.1 22.3 39.7 22.2 78.3 27.4 
Meliaceae Turraea floribunda Hochst. Roots DCM/MeOH (1:1) P05329B 64.4 10.0 18.3 18.8 53.6 21.3 98.9 58.6 
Rubiaceae Vangueria infausta  Fruits DCM P00008A 29.5 18.9 31.2 7.4 0.0 0.0 35.7 3.1 
Rubiaceae Vangueria infausta  Fruits DCM/MeOH (1:1) P00008B 21.6 13.3 43.1 14.1 23.1 20.0 33.6 2.6 
Rubiaceae Vangueria infausta  Fruits MeOH P00008C 17.3 7.6 45.0 16.0 31.5 21.4 30.4 0.0 
Rubiaceae Vangueria infausta  Roots DCM/MeOH (1:1) P09344B 17.4 5.2 37.4 14.6 16.8 0.0 44.6 14.1 
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Rubiaceae Vangueria infausta  Stems DCM/MeOH (1:1) P09345B 22.2 10.2 38.1 14.9 38.1 17.3 43.9 11.6 
Rubiaceae Vangueria infausta  Leaves DCM/MeOH (1:1) P09346B 99.2 0.0 36.9 10.5 45.5 19.8 52.9 15.2 
Asteraceae Vernonia mespilifolia Less Leaves DCM/MeOH (1:1) P11137B 100.0 100.0 90.1 34.5 100.0 29.5 96.6 32.5 
Asteraceae Vernonia mespilifolia Less Stems DCM/MeOH (1:1) P11138B 95.1 0.0 35.1 25.9 84.5 29.8 55.8 8.4 
Asteraceae Vernonia mespilifolia Less Roots DCM/MeOH (1:1) P11139B 16.8 0.0 38.9 21.5 36.4 26.1 48.4 9.6 
Asteraceae Vernonia myriantha Roots DCM P00170A 7.7 0.0 37.4 14.5 0.0 0.0 36.9 15.8 
Asteraceae Vernonia myriantha Roots DCM/MeOH (1:1) P00170B 13.6 4.3 46.0 24.6 32.5 17.0 37.0 12.2 
Asteraceae Vernonia myriantha Leaves DCM P00171A 8.6 0.0 36.5 19.3 39.0 16.6 59.5 7.5 
Asteraceae Vernonia myriantha Leaves DCM/MeOH (1:1) P00171B 1.5 0.0 30.5 22.1 36.0 21.5 29.2 1.9 
Asteraceae Vernonia myriantha Leaves MeOH P00171C 0.2 0.0 39.1 23.5 36.4 26.5 26.3 6.2 
Asteraceae Vernonia myriantha Stems DCM P00172A 5.3 0.0 40.0 17.0 37.4 25.6 32.6 14.9 
Asteraceae Vernonia myriantha Stems MeOH P00172C 0.0 0.0 43.2 14.8 32.6 21.1 17.0 0.0 
Asteraceae Vernonia myriantha Seeds DCM P00173A 0.0 0.0 39.6 20.0 35.7 19.0 32.9 0.4 
Asteraceae Vernonia myriantha Seeds DCM/MeOH (1:1) P00173B 0.0 0.0 35.8 18.1 38.0 22.1 36.9 0.1 
Olacaceae Ximenia caffra  Leaves DCM/MeOH (1:1) P03508B 25.3 15.2 42.7 17.3 33.9 26.7 51.9 0.0 
Olacaceae Ximenia  Twigs  DCM/MeOH (1:1) P03509B 40.7 0.0 32.7 10.8 0.0 0.0 50.1 9.2 
rutaceae Zanthoxylum capense Leaves DCM/MeOH (1:1) P07947B 34.0 0.0 39.5 16.6 46.1 30.1 99.7 38.8 
rutaceae Zanthoxylum capense Stems DCM/MeOH (1:1) P07948B 27.5 5.7 39.0 18.8 51.7 27.0 95.4 40.0 
rutaceae Zanthoxylum capense Roots DCM/MeOH (1:1) P07949B 11.6 34.3 44.2 7.2 47.5 29.3 86.1 32.5 
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rutaceae Zanthoxylum capense Fruits DCM/MeOH (1:1) P07950B 7.2 0.0 37.1 19.8 36.2 27.9 70.0 14.3 
rutaceae Zanthoxylum davyi  Leaves DCM/MeOH (1:1) P10430B 49.3 2.2 35.7 12.7 88.9 30.3 82.2 25.4 
Rutaceae Zanthoxylum davyi  Fruits DCM/MeOH (1:1) P10431B 5.2 0.0 32.0 7.9 30.4 26.1 44.3 8.5 
Rutaceae Zanthoxylum davyi stems DCM/MeOH (1:1) P10432B 23.7 14.8 39.0 18.4 34.3 16.9 84.0 30.1 
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Table 4.2 The IC50 values (µg/mL), selectivity index and cytotoxicity of 18 South African plant species against Trypanosoma brucei 
rhodesiense, Trypanosoma cruzi, Leishmania donovani, Plasmodium falciparum and myoblast L6 cells. The positive controls 
melarsoprola, benznidazoleb, miltefosinec, chloroquined and podophyllotoxine were tested likewise. Tests were done twice in duplicate. 




Family Plant species Plant part Extract type IC50 SI IC50 SI IC50 SI IC50 SI IC50 
Sapindaceae Pappea capensis Roots DCM 15.40±1.84 2.43     10.10±2.79 3.70 37.40±22.42 
Anacardiace
ae 
Ozoroa sphaerocarpa Whole 
plant 
DCM 10.90±7.09 4.76   5.78±0.25 8.98 12.90±7.42 4.02 51.90±3.75 
Fabaceae  Acacia erioloba Roots DCM/MeOH 
(1:1) 
  18.50±11.29 3.01   10.70±2.74 5.21 55.70±7.92 
Fabaceae Psoralea pinnata Leaves DCM 0.15±0.02 97.32   5.08±0.11 2.85 8.46±5.03 1.71 14.50±2.83 
Fabaceae Psoralea pinnata Leaves DCM/MeOH 
(1:1) 
0.31±0.02 139.61   6.73±0.16 6.39 9.18±1.61 4.68 43.00±14.64 




4.38±1.87 11.16 31.40±12.10 1.56 1.71±0.02 28.60 2.88±1.37 16.98 48.90±9.55 






1.04±0.45 48.17   8.84±0.11 5.67 3.39±0.07 14.78 50.10±2.05 
Euphorbiace
ae 
Clutia pulchella pulchella Roots DCM/MeOH 
(1:1) 
      3.19±0.94 28.21 90.00±14.21 
Euphorbiace
ae 




      14.10±5.73 3.74 52.70±1.20 




2.04±0.02 8.63 17.90±10.02 0.98 10.80±4.05 1.63 2.19±0.48 8.04 17.60±0.99 
Rutaceae Clausena anisata anisata Roots DCM/MeOH 
(1:1) 
7.19±0.95 3.59   11.50±5.21 2.24 3.61±1.82 7.15 25.80±5.73 
Meliaceae Ekebergia capensis Roots DCM/MeOH 
(1:1) 
1.36±0.85 24.26 17.40±2.78 1.90 6.42±2.59 5.14 6.81±3.92 4.85 33.00±23.41 
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2.28     4.52±0.53 12.32 55.70±16.26 
Meliaceae Turraea floribunda Leaves DCM/MeOH 
(1:1) 
17.10±1.06 2.82     12.70±5.24 3.80 48.30±6.58 
Meliaceae Turraea floribunda Roots DCM/MeOH 
(1:1) 
22.40±6.58 2.36   13.10±4.17 4.03 5.56±2.91 9.50 52.80±7.00 
Meliaceae Drypetes gerrardii  Stems DCM/MeOH 
(1:1) 
8.39±5.54 6.05   7.31±0.85 6.95 0.50±0.23 101.20 50.80±1.77 
Meliaceae Drypetes gerrardii  Leaves DCM/MeOH 
(1:1) 







    13.50±2.90 4.29 6.46±3.44 8.96 57.90±11.17 
Sapindaceae Pappea capensis Roots DCM/MeOH 
(1:1) 
      5.30±1.75 16.00 84.80±21.57 
Sapindaceae Pappea capensis Leaves DCM/MeOH 
(1:1) 
14.10±4.24 5.43     9.67±0.38 7.91 76.50±33.16 




1.01±0.31 14.65 8.76±12.01 1.69 2.48±0.33 5.97 5.09±1.86 2.91 14.80±3.25 
 Standard drug   0.002±0.00a  0.355±0.09b  0.179±0.02c  0.003±0.00
d 
 0.008±0.00e 
 
